158681-13-1 | 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
5g	96%	in stock	$34.00	$24.00
25g	96%	in stock	$66.00	$47.00
100g	96%	in stock	$203.00	$142.00

Description

• Catalog Number: AA81109
• Chemical Name: 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide hydrochloride
• CAS Number: 158681-13-1
• Molecular Formula: C22H22Cl4N4O
• Molecular Weight: 500.2483
• MDL Number: MFCD00934884
• SMILES: Clc1ccc(cc1)c1c(C)c(nn1c1ccc(cc1Cl)Cl)C(=O)NN1CCCCC1.Cl

Computed Properties

• Complexity: 583
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 31
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4

Literature

• WWL70 attenuates PGE(2) production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism.

  Journal of neuroinflammation 20170101

• Parabens inhibit fatty acid amide hydrolase: A potential role in paraben-enhanced 3T3-L1 adipocyte differentiation.

  Toxicology letters 20161116

• Cannabinoid receptor interacting protein suppresses agonist-driven CB(1) receptor internalization and regulates receptor replenishment in an agonist-biased manner.

  Journal of neurochemistry 20161101

• In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048).

  The Journal of pharmacology and experimental therapeutics 20161001

• Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats.

  British journal of pharmacology 20130601

• Structural analogs of pyrazole and sulfonamide cannabinoids: effects on acute food intake in mice.

  European journal of pharmacology 20121115

• Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).

  Family practice 20121001

• The effects of fasting duration on gastric emptying in man, an exploration of the role of the endocannabinoid system and inter-individual responsiveness.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20121001

• AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

  Neuropharmacology 20121001

• NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.

  Behavioural brain research 20121001

• Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice.

  Behavioural pharmacology 20121001

• [Effect of metabolic drugs on the secretion of acylation stimulating protein in 3T3-L1 adipocytes].

  Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 20121001

• Angiotensin II induces vascular endocannabinoid release, which attenuates its vasoconstrictor effect via CB1 cannabinoid receptors.

  The Journal of biological chemistry 20120907

• Fatty acid flux and oxidation are increased by rimonabant in obese women.

  Metabolism: clinical and experimental 20120901

• Cannabinol and cannabidiol exert opposing effects on rat feeding patterns.

  Psychopharmacology 20120901

• Cannabinoid receptors mediate methamphetamine induction of high frequency gamma oscillations in the nucleus accumbens.

  Neuropharmacology 20120901

• Selective cannabinoid-1 receptor blockade benefits fatty acid and triglyceride metabolism significantly in weight-stable nonhuman primates.

  American journal of physiology. Endocrinology and metabolism 20120901

• Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice.

  Endocrinology 20120901

• Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.

  Expert opinion on investigational drugs 20120901

• Anandamide regulates the expression of GnRH1, GnRH2, and GnRH-Rs in frog testis.

  American journal of physiology. Endocrinology and metabolism 20120815

• Effect of CB1 receptor blockade on food-reinforced responding and associated nucleus accumbens neuronal activity in rats.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120815

• Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.

  Psychopharmacology 20120801

• Inhibition of forebrain μ-opioid receptor signaling by low concentrations of rimonabant does not require cannabinoid receptors and directly involves μ-opioid receptors.

  Neurochemistry international 20120801

• Antidepressant-like effects of Δ⁹-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression.

  Pharmacology, biochemistry, and behavior 20120801

• Inhibition of fatty acid amide hydrolase by URB597 attenuates the anxiolytic-like effect of acetaminophen in the mouse elevated plus-maze test.

  Behavioural pharmacology 20120801

• Cannabinoid receptor 1 in the vagus nerve is dispensable for body weight homeostasis but required for normal gastrointestinal motility.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120725

• Activation of type 5 metabotropic glutamate receptors and diacylglycerol lipase-α initiates 2-arachidonoylglycerol formation and endocannabinoid-mediated analgesia.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120711

• Cannabinoid CB₁ receptor restrains accentuated activity of hypothalamic corticotropin-releasing factor and brainstem tyrosine hydroxylase neurons in endotoxemia-induced hypophagia in rats.

  Neuropharmacology 20120701

• Photoperiodic changes in endocannabinoid levels and energetic responses to altered signalling at CB1 receptors in Siberian hamsters.

  Journal of neuroendocrinology 20120701

• Genetic dissection of the role of cannabinoid type-1 receptors in the emotional consequences of repeated social stress in mice.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120701

• Involvement of a non-CB1/CB2 cannabinoid receptor in the aqueous humor outflow-enhancing effects of abnormal-cannabidiol.

  Experimental eye research 20120701

• Effects of palmitoylethanolamide on aqueous humor outflow.

  Investigative ophthalmology & visual science 20120701

• Presynaptic CB(1) cannabinoid receptors control frontocortical serotonin and glutamate release--species differences.

  Neurochemistry international 20120701

• A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20120601

• Methamphetamine-induced dopamine terminal deficits in the nucleus accumbens are exacerbated by reward-associated cues and attenuated by CB1 receptor antagonism.

  Neuropharmacology 20120601

• Rimonabant abolishes sensitivity to workload changes in a progressive ratio procedure.

  Pharmacology, biochemistry, and behavior 20120601

• Addition of a low dose of rimonabant to orlistat therapy decreases weight gain and reduces adiposity in dietary obese rats.

  Clinical and experimental pharmacology & physiology 20120601

• Pleiotropic effects of rimonabant and simvastatin on obesity associated multiple metabolic risk factors in rats.

  European review for medical and pharmacological sciences 20120601

• CB(1) antagonism restores hepatic insulin sensitivity without normalization of adiposity in diet-induced obese dogs.

  American journal of physiology. Endocrinology and metabolism 20120515

• Exploiting transport activity of p-glycoprotein at the blood-brain barrier for the development of peripheral cannabinoid type 1 receptor antagonists.

  Molecular pharmaceutics 20120507

• Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor.

  The Journal of biological chemistry 20120504

• Effects of chronic oral rimonabant administration on energy budgets of diet-induced obese C57BL/6 mice.

  Obesity (Silver Spring, Md.) 20120501

• CB1 receptor antagonists: new discoveries leading to new perspectives.

  Acta physiologica (Oxford, England) 20120501

• Food and Drug Administration's Obesity Drug Guidance Document: a short history.

  Circulation 20120501

• Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.

  The Journal of biological chemistry 20120406

• The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors.

  British journal of pharmacology 20120401

• The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nociceptive tone.

  British journal of pharmacology 20120401

• The GPCR-associated sorting protein 1 regulates ligand-induced down-regulation of GPR55.

  British journal of pharmacology 20120401

• Tonic regulation of GABAergic synaptic activity on vasopressin neurones by cannabinoids.

  Journal of neuroendocrinology 20120401

• Inhibitory inputs from rostromedial tegmental neurons regulate spontaneous activity of midbrain dopamine cells and their responses to drugs of abuse.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20120401

• Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor.

  Naunyn-Schmiedeberg's archives of pharmacology 20120401

• [The potential use of cannabidiol in the therapy of metabolic syndrome].

  Orvosi hetilap 20120401

• [The pharmacological treatment of obesity: past, present and future].

  Orvosi hetilap 20120311

• Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants.

  Hepatology (Baltimore, Md.) 20120301

• The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.

  Pharmacological research 20120301

• Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration.

  Pharmacology, biochemistry, and behavior 20120301

• Does rimonabant independently affect free fatty acid and glucose metabolism?

  The Journal of clinical endocrinology and metabolism 20120301

• Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.

  The Journal of pharmacology and experimental therapeutics 20120301

• Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis.

  Laboratory investigation; a journal of technical methods and pathology 20120301

• Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice.

  Endocrinology 20120301

• Changes in cannabinoid receptor subtype 1 activity and interaction with metabotropic glutamate subtype 5 receptors in the periaqueductal gray-rostral ventromedial medulla pathway in a rodent neuropathic pain model.

  CNS & neurological disorders drug targets 20120301

• Rimonabant reduces the essential value of food in the genetically obese Zucker rat: an exponential demand analysis.

  Physiology & behavior 20120201

• 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.

  The Journal of pharmacology and experimental therapeutics 20120201

• Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

  Schizophrenia research 20120201

• Cannabinoid CB1 receptor mediates glucocorticoid effects on hormone secretion induced by volume and osmotic changes.

  Clinical and experimental pharmacology & physiology 20120201

• Blocking the postpartum mouse dam's CB1 receptors impairs maternal behavior as well as offspring development and their adult social-emotional behavior.

  Behavioural brain research 20120115

• The inverse agonist effect of rimonabant on G protein activation is not mediated by the cannabinoid CB1 receptor: evidence from postmortem human brain.

  Biochemical pharmacology 20120115

• Δ9-Tetrahydrocannabinol attenuates MDMA-induced hyperthermia in rhesus monkeys.

  Neuroscience 20120110

• SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance.

  Nature neuroscience 20120108

• Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.

  The Journal of biological chemistry 20120102

• Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats.

  Addiction biology 20120101

• Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.

  Journal of psychopharmacology (Oxford, England) 20120101

• Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking.

  Addiction biology 20120101

• CB1 receptor antagonism/inverse agonism increases motor system excitability in humans.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20120101

• The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment.

  Angiology 20120101

• CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men.

  The American journal of drug and alcohol abuse 20120101

• Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist.

  Journal of neuroscience research 20120101

• Rimonabant attenuates amphetamine sensitisation in a CCK2 receptor-dependent manner.

  Behavioural brain research 20120101

• Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats.

  European urology 20120101

• JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.

  The Journal of pharmacology and experimental therapeutics 20120101

• The effects of chronic administration of tranylcypromine and rimonabant on behaviour and protein expression in brain regions of the rat.

  Pharmacology, biochemistry, and behavior 20120101

• Does innovation in obesity drugs affect stock markets? An event study analysis.

  Gaceta sanitaria 20120101

• Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice.

  PloS one 20120101

• What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review.

  Health technology assessment (Winchester, England) 20120101

• Effects of cannabinoid receptor agonist WIN 55,212-2 on blood-brain barrier disruption in focal cerebral ischemia in rats.

  Pharmacology 20120101

• Induction of glucose intolerance by acute administration of rimonabant.

  Pharmacology 20120101

• Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.

  Current pharmaceutical design 20120101

• Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies.

  Current pharmaceutical design 20120101

• Targeted inactivation of GPR26 leads to hyperphagia and adiposity by activating AMPK in the hypothalamus.

  PloS one 20120101

• Relationships between glucose, energy intake and dietary composition in obese adults with type 2 diabetes receiving the cannabinoid 1 (CB1) receptor antagonist, rimonabant.

  Nutrition journal 20120101

• Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice.

  International journal of obesity (2005) 20111201

• Retinol-binding protein 4 : a possible role in cardiovascular complications.

  British journal of pharmacology 20111201

• Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.

  Psychopharmacology 20111201

• Naloxone and rimonabant reduce the reinforcing properties of exercise in rats.

  Experimental and clinical psychopharmacology 20111201

• Endocannabinoids and prostaglandins both contribute to GnRH neuron-GABAergic afferent local feedback circuits.

  Journal of neurophysiology 20111201

• Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.

  Naunyn-Schmiedeberg's archives of pharmacology 20111201

• Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.

  Diabetologia 20111201

• ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data.

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20111201

• Positron emission tomographic imaging of the cannabinoid type 1 receptor system with [¹¹C]OMAR ([¹¹C]JHU75528): improvements in image quantification using wild-type and knockout mice.

  Molecular imaging 20111201

• Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition.

  Molecular pharmacology 20111101

• Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.

  The Journal of pharmacology and experimental therapeutics 20111101

• Large size cells in the visceral adipose depot predict insulin resistance in the canine model.

  Obesity (Silver Spring, Md.) 20111101

• Effects of the cannabinoid antagonist SR 141716 on sexual and motor behaviour in receptive female rats.

  Clinical and experimental pharmacology & physiology 20111101

• Negative inotropic effect of a CB2 agonist A-955840 in isolated rabbit ventricular myocytes is independent of CB1 and CB2 receptors.

  Current drug safety 20111101

• The endocannabinoid 2-arachidonoylglycerol mediates D1 and D2 receptor cooperative enhancement of rat nucleus accumbens core neuron firing.

  Neuroscience 20111013

• CRIP1a switches cannabinoid receptor agonist/antagonist-mediated protection from glutamate excitotoxicity.

  Neuroscience letters 20111010

• Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors.

  Nature medicine 20111002

• delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory.

  Psychopharmacology 20111001

• Activation by 2-arachidonoylglycerol of platelet p38MAPK/cPLA2 pathway.

  Journal of cellular biochemistry 20111001

• Cannabinoid CB1 receptor antagonist rimonabant disrupts nicotine reward-associated memory in rats.

  Pharmacology, biochemistry, and behavior 20111001

• Pro-epileptic effects of the cannabinoid receptor antagonist SR141716 in a model of audiogenic epilepsy.

  Epilepsy research 20111001

• Bioactivation pathways of the cannabinoid receptor 1 antagonist rimonabant.

  Drug metabolism and disposition: the biological fate of chemicals 20111001

• The G protein-coupled cannabinoid-1 (CB1) receptor of mammalian brain: inhibition by phthalate esters in vitro.

  Neurochemistry international 20111001

• The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.

  Obesity (Silver Spring, Md.) 20111001

• CNS opioid signaling separates cannabinoid receptor 1-mediated effects on body weight and mood-related behavior in mice.

  Endocrinology 20111001

• Antagonist-elicited cannabis withdrawal in humans.

  Journal of clinical psychopharmacology 20111001

• Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity.

  Bioorganic & medicinal chemistry letters 20111001

• Retention and extinction of delay eyeblink conditioning are modulated by central cannabinoids.

  Learning & memory (Cold Spring Harbor, N.Y.) 20111001

• [The role of the cannabinoid system in the pathogenesis and treatment of alcohol dependence].

  Postepy higieny i medycyny doswiadczalnej (Online) 20110916

• The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys.

  British journal of pharmacology 20110901

• Extinction learning of rewards in the rat: is there a role for CB1 receptors?

  Psychopharmacology 20110901

• Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats.

  Pharmacological research 20110901

• Dissimilar cannabinoid substitution patterns in mice trained to discriminate Δ(9)-tetrahydrocannabinol or methanandamide from vehicle.

  Behavioural pharmacology 20110901

• Cannabinergic aminoalkylindoles, including AM678=JWH018 found in 'Spice', examined using drug (Δ(9)-tetrahydrocannabinol) discrimination for rats.

  Behavioural pharmacology 20110901

• Direct injection of lipophilic compounds in the organic phase from liquid-liquid extracted plasma samples onto a reversed-phase column.

  Bioanalysis 20110901

• CB1 receptors mediate rimonabant-induced pruritic responses in mice: investigation of locus of action.

  Psychopharmacology 20110801

• Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.

  Psychopharmacology 20110801

• Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats.

  British journal of pharmacology 20110801

• Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20110801

• Memory encoding in hippocampal ensembles is negatively influenced by cannabinoid CB1 receptors.

  Behavioural pharmacology 20110801

• [Pharmacological concepts for the treatment of obesity - a therapeutic meander?].

  Deutsche medizinische Wochenschrift (1946) 20110801

• CB-1 receptors modulate the effect of the selective serotonin reuptake inhibitor, citalopram on extracellular serotonin levels in the rat prefrontal cortex.

  Neuroscience research 20110701

• Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.

  Obesity (Silver Spring, Md.) 20110701

• Effect of rimonabant on carotid intima-media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial.

  Heart (British Cardiac Society) 20110701

• Tolerance and cross-tolerance to cannabinoids in mice: schedule-controlled responding and hypothermia.

  Psychopharmacology 20110601

• Effects of morphine on pain-elicited and pain-suppressed behavior in CB1 knockout and wildtype mice.

  Psychopharmacology 20110601

• Disruptive effects of the prototypical cannabinoid Δ⁹-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats.

  Behavioural pharmacology 20110601

• Propofol enhances memory formation via an interaction with the endocannabinoid system.

  Anesthesiology 20110601

• Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study.

  International journal of clinical practice 20110601

• Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England.

  Drug safety 20110601

• Leptin potentiates the anti-obesity effects of rimonabant.

  European journal of pharmacology 20110511

• The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110511

• Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity.

  Neuropharmacology 20110501

• The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors.

  The Journal of physiology 20110501

• Personalized medicine can pave the way for the safe use of CB₁ receptor antagonists.

  Trends in pharmacological sciences 20110501

• Acute treatment with cannabinoid receptor agonist WIN55212.2 improves prepulse inhibition in psychosocially stressed mice.

  Behavioural brain research 20110415

• Design, synthesis and biological evaluation of CB1 cannabinoid receptor ligands derived from the 1,5-diarylpyrazole scaffold.

  Journal of enzyme inhibition and medicinal chemistry 20110401

• Binding properties of antagonists to cannabinoid receptors in intact cells.

  Fundamental & clinical pharmacology 20110401

• Sensitization to cocaine is inhibited after intra-accumbal GR103691 or rimonabant, but it is enhanced after co-infusion indicating functional interaction between accumbens D(3) and CB1 receptors.

  Psychopharmacology 20110401

• Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition.

  Pharmacology, biochemistry, and behavior 20110401

• Feedback and lessons from the prescription of rimonabant, a drug to be used under strict guidelines, in southeastern France, March 2007 through June 2008.

  Revue d'epidemiologie et de sante publique 20110401

• Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis.

  Diabetes 20110401

• Investigations of the endocannabinoid system in adipose tissue: effects of obesity/ weight loss and treatment options.

  Danish medical bulletin 20110401

• [Anandamide inhibits the growth of colorectal cancer cells through CB1 and lipid rafts].

  Zhonghua zhong liu za zhi [Chinese journal of oncology] 20110401

• Endocannabinoid 2-arachidonoylglycerol protects neurons against β-amyloid insults.

  Neuroscience 20110331

• Cannabinoid type 1 receptor antagonists for smoking cessation.

  The Cochrane database of systematic reviews 20110316

• Pharmacological activation of kainate receptors drives endocannabinoid mobilization.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20110302

• Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.

  Obesity (Silver Spring, Md.) 20110301

• Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice.

  Psychopharmacology 20110301

• Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.

  Behavioural brain research 20110301

• Chronic Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys: differential tolerance and cross-tolerance among cannabinoids.

  British journal of pharmacology 20110301

• Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay.

  Pharmacology, biochemistry, and behavior 20110301

• Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.

  British journal of pharmacology 20110301

• Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure.

  The Journal of clinical endocrinology and metabolism 20110301

• Effect of rimonabant on oesophageal motor function in man.

  Alimentary pharmacology & therapeutics 20110301

• [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].

  Ugeskrift for laeger 20110221

• Effects of cannabinoid CB₁ receptor antagonist rimonabant on acquisition and reinstatement of psychostimulant reward memory in mice.

  Behavioural brain research 20110202

• Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20110201

• Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study.

  Journal of clinical psychopharmacology 20110201

• An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity.

  Journal of clinical pharmacy and therapeutics 20110201

• Pharmacotherapy for obese adolescents.

  Pediatric clinics of North America 20110201

• The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.

  Oncogene 20110113

• The identification of rimonabant polymorphs, sibutramine and analogues of both in counterfeit Acomplia bought on the internet.

  Journal of pharmaceutical and biomedical analysis 20110105

• The CB₁ receptor antagonist SR141716A reverses adult male mice overweight and metabolic alterations induced by early stress.

  Obesity (Silver Spring, Md.) 20110101

• The CB-1 receptor antagonist rimonabant modulates the interaction between adipocytes and pancreatic beta-cells in vitro.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20110101

• The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.

  Neuropharmacology 20110101

• Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice.

  British journal of pharmacology 20110101

• Upregulation of cannabinoid type 1 receptors in dopamine D2 receptor knockout mice is reversed by chronic forced ethanol consumption.

  Alcoholism, clinical and experimental research 20110101

• Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome.

  European journal of medical genetics 20110101

• Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys.

  Neuropharmacology 20110101

• The role of endocannabinoids in visceral hyposensitivity induced by rapid eye movement sleep deprivation in rats: regional differences.

  International journal of molecular medicine 20110101

• Metformin may maintain weight loss in obese patients with dysglycaemia initially treated with rimonabant.

  Diabetic medicine : a journal of the British Diabetic Association 20110101

• Molecular mechanisms for the destabilization and restabilization of reactivated spatial memory in the Morris water maze.

  Molecular brain 20110101

• Bioequivalence study of two tablet formulations containing rimonabant 20 mg in healthy Indian subjects.

  Arzneimittel-Forschung 20110101

• Endocannabinoid system protects against cryptogenic seizures.

  Pharmacological reports : PR 20110101

• Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice.

  PloS one 20110101

• Pharmacological evidence for different populations of postsynaptic adenosine A2A receptors in the rat striatum.

  Neuropharmacology 20110101

• AM251, cannabinoids receptors ligand, improves recognition memory in rats.

  Pharmacological reports : PR 20110101

• Cannabinoid receptor type I modulates alcohol-induced liver fibrosis.

  Molecular medicine (Cambridge, Mass.) 20110101

• Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults.

  PloS one 20110101

• Effects of cannabinoid agonists on sheep sphincter of oddi in vitro.

  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 20110101

• Cannabinoid CB1 receptor activation mediates the opposing effects of amphetamine on impulsive action and impulsive choice.

  PloS one 20110101

• Termination of the CRESCENDO trial.

  Lancet (London, England) 20101211

• Termination of the CRESCENDO trial.

  Lancet (London, England) 20101211

• The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.

  Brain research 20101202

• Reversal of inflammation-induced impairment of glucose uptake in adipocytes by direct effect of CB1 antagonism on adipose tissue macrophages.

  Obesity (Silver Spring, Md.) 20101201

• Antagonism of ∆⁹-THC induced behavioral effects by rimonabant: time course studies in rats.

  European journal of pharmacology 20101201

• Energetic metabolism and human sperm motility: impact of CB₁ receptor activation.

  Endocrinology 20101201

• Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties.

  European journal of immunology 20101201

• Identification of amino-tadalafil and rimonabant in electronic cigarette products using high pressure liquid chromatography with diode array and tandem mass spectrometric detection.

  Journal of chromatography. A 20101126

• Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats.

  European journal of pharmacology 20101110

• Effects of acute low-dose combined treatment with rimonabant and sibutramine on appetite and weight gain in rats.

  Pharmacology, biochemistry, and behavior 20101101

• Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ(9)-tetrahydrocannabinol.

  Drug and alcohol dependence 20101101

• Tuberoinfundibular peptide of 39 residues (TIP39) signaling modulates acute and tonic nociception.

  Experimental neurology 20101101

• Chronic treatment with the cannabinoid 1 antagonist rimonabant altered vasoactive cyclo-oxygenase-derived products on arteries from obese Zucker rats.

  Journal of cardiovascular pharmacology 20101101

• Peripheral endocannabinoid system-mediated actions of rimonabant on growth hormone secretion are ghrelin-dependent.

  Journal of neuroendocrinology 20101101

• Cannabinoids reveal separate controls for whisking amplitude and timing in rats.

  Journal of neurophysiology 20101101

• Human platelets express authentic CB₁ and CB₂ receptors.

  Current neurovascular research 20101101

• Rimonabant inhibits TNF-α-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway.

  Acta pharmacologica Sinica 20101101

• Central cannabinoid receptors modulate acquisition of eyeblink conditioning.

  Learning & memory (Cold Spring Harbor, N.Y.) 20101101

• Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism.

  Nature neuroscience 20101001

• Relapse prevention in UK Stop Smoking Services: current practice, systematic reviews of effectiveness and cost-effectiveness analysis.

  Health technology assessment (Winchester, England) 20101001

• Regulation of subthalamic neuron activity by endocannabinoids.

  Synapse (New York, N.Y.) 20100901

• Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers.

  The international journal of neuropsychopharmacology 20100901

• Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100901

• Regional enhancement of cannabinoid CB₁ receptor desensitization in female adolescent rats following repeated Delta-tetrahydrocannabinol exposure.

  British journal of pharmacology 20100901

• Rimonabant: obituary for a wonder drug.

  Lancet (London, England) 20100814

• Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial.

  Lancet (London, England) 20100814

• Rimonabant is a dual inhibitor of acyl CoA:cholesterol acyltransferases 1 and 2.

  Biochemical and biophysical research communications 20100806

• Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?

  The Journal of clinical investigation 20100802

• Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.

  The Journal of clinical investigation 20100802

• Δ⁹-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats.

  Epilepsia 20100801

• Depression-like phenotype following chronic CB1 receptor antagonism.

  Neurobiology of disease 20100801

• Rimonabant-induced apoptosis in leukemia cell lines: activation of caspase-dependent and -independent pathways.

  Biochemical pharmacology 20100801

• The endocannabinoid system tonically regulates inhibitory transmission and depresses the effect of ethanol in central amygdala.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100801

• Rimonabant-mediated changes in intestinal lipid metabolism and improved renal vascular dysfunction in the JCR:LA-cp rat model of prediabetic metabolic syndrome.

  American journal of physiology. Gastrointestinal and liver physiology 20100801

• Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif.

  Bioorganic & medicinal chemistry letters 20100801

• Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle.

  Diabetes, obesity & metabolism 20100801

• A systematic review of the effectiveness of smoking relapse prevention interventions for abstinent smokers.

  Addiction (Abingdon, England) 20100801

• Rimonabant, a cannabinoid CB1 receptor antagonist, attenuates mechanical allodynia and counteracts oxidative stress and nerve growth factor deficit in diabetic mice.

  European journal of pharmacology 20100710

• Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat.

  European journal of pharmacology 20100710

• Differential effects of CB(1) neutral antagonists and inverse agonists on gastrointestinal motility in mice.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100701

• CB(1) modulation of hormone secretion, neuronal activation and mRNA expression following extracellular volume expansion.

  Experimental neurology 20100701

• TrkB agonist antibody dose-dependently raises blood pressure in mice with diet-induced obesity.

  American journal of hypertension 20100701

• FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20100701

• CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function.

  Basic research in cardiology 20100701

• Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.

  The Journal of pharmacology and experimental therapeutics 20100701

• Altered architecture and functional consequences of the mesolimbic dopamine system in cannabis dependence.

  Addiction biology 20100701

• Additive actions of the cannabinoid and neuropeptide Y systems on adiposity and lipid oxidation.

  Diabetes, obesity & metabolism 20100701

• Therapeutic approaches to epileptogenesis--hope on the horizon.

  Epilepsia 20100701

• CB1 receptor antagonism impairs the induction of epileptiform activity by group I metabotropic glutamate receptor activation.

  Epilepsia 20100701

• The effect of the cannabinoid-receptor antagonist, SR141716, on the early stage of kainate-induced epileptogenesis in the adult rat.

  Epilepsia 20100701

• Quantification of rimonabant (SR 141716A) in monkey plasma using HPLC with UV detection.

  Journal of chromatographic science 20100701

• The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.

  European journal of pharmacology 20100625

• Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice.

  Brain research 20100621

• GPR55 ligands promote receptor coupling to multiple signalling pathways.

  British journal of pharmacology 20100601

• Enhanced cognitive performance of dopamine D3 receptor 'knock-out' mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems.

  Pharmacological research 20100601

• Cannabinoid 1 receptors modulate intestinal sensory and motor function in rat.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20100601

• Rimonabant during early pregnancy.

  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20100601

• Direct and indirect effects of cannabinoids on in vitro GABA release in the rat arcuate nucleus.

  Journal of neuroendocrinology 20100601

• Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.

  Psychopharmacology 20100601

• How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue.

  Drug discovery today 20100601

• Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation.

  British journal of pharmacology 20100601

• CB1 cannabinoid receptors promote oxidative/nitrosative stress, inflammation and cell death in a murine nephropathy model.

  British journal of pharmacology 20100601

• Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells.

  British journal of pharmacology 20100601

• Endocannabinoid modulation of hyperaemia evoked by physiologically relevant stimuli in the rat primary somatosensory cortex.

  British journal of pharmacology 20100601

• Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.

  British journal of pharmacology 20100601

• The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20100526

• Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze.

  Neuroscience letters 20100521

• Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys.

  European journal of pharmacology 20100510

• Intra-accumbens rimonabant is rewarding but induces aversion to cocaine in cocaine-treated rats, as does in vivo accumbal cannabinoid CB1 receptor silencing: critical role for glutamate receptors.

  Neuroscience 20100505

• Effects of intra-basolateral amygdala administration of rimonabant on nociceptive behaviour and neuronal activity in the presence or absence of contextual fear.

  European journal of pain (London, England) 20100501

• Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.

  Angiology 20100501

• A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy.

  Pharmacological research 20100501

• Endocannabinoid control of gastric sensorimotor function in man.

  Alimentary pharmacology & therapeutics 20100501

• Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses.

  Nature neuroscience 20100501

• [Therapeutical use of the cannabinoids in psychiatry].

  Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20100501

• WIN55,212-2 induced deficits in spatial learning are mediated by cholinergic hypofunction.

  Behavioural brain research 20100402

• A metabolically stable analogue of anandamide, Met-F-AEA, inhibits human thyroid carcinoma cell lines by activation of apoptosis.

  Investigational new drugs 20100401

• A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden.

  The European journal of health economics : HEPAC : health economics in prevention and care 20100401

• Unravelling the complex dissociation of [(3)H]-rimonabant from plated CB(1) cannabinoid receptor-expressing cells.

  Fundamental & clinical pharmacology 20100401

• Resistance to epinephrine and hypersensitivity (hyperresponsiveness) to CB1 antagonists in a patient with pseudohypoparathyroidism type Ic.

  European journal of endocrinology 20100401

• CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice.

  Diabetes 20100401

• The antinociceptive effect of acetylsalicylic acid is differently affected by a CB1 agonist or antagonist and involves the serotonergic system in rats.

  Life sciences 20100327

• Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome.

  Clinical endocrinology 20100301

• Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial.

  Diabetes care 20100301

• Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study.

  Pharmacoepidemiology and drug safety 20100301

• Central and peripheral consequences of the chronic blockade of CB1 cannabinoid receptor with rimonabant or taranabant.

  Journal of neurochemistry 20100301

• FAAH deficiency promotes energy storage and enhances the motivation for food.

  International journal of obesity (2005) 20100301

• Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.

  International journal of obesity (2005) 20100301

• Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway.

  Neurochemistry international 20100301

• Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data.

  CNS & neurological disorders drug targets 20100301

• Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.

  The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 20100301

• Cannabinoid 1 receptor blockade reduces atherosclerosis with enhances reverse cholesterol transport.

  Journal of atherosclerosis and thrombosis 20100226

• Aspirin-triggered lipoxin induces CB1-dependent catalepsy in mice.

  Neuroscience letters 20100205

• Metabolic responses to long-term pharmacological inhibition of CB1-receptor activity in mice in relation to dietary fat composition.

  International journal of obesity (2005) 20100201

• Expression and function of endocannabinoid receptors in the human adrenal cortex.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100201

• Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference.

  Progress in neuro-psychopharmacology & biological psychiatry 20100201

• Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes.

  Diabetes, obesity & metabolism 20100201

• Human sperm anatomy: ultrastructural localization of the cannabinoid1 receptor and a potential role of anandamide in sperm survival and acrosome reaction.

  Anatomical record (Hoboken, N.J. : 2007) 20100201

• Rimonabant (SR141716) induces metabolism and acquisition of fertilizing ability in human sperm.

  British journal of pharmacology 20100201

• Cue-conditioned alcohol seeking in rats following abstinence: involvement of metabotropic glutamate 5 receptors.

  British journal of pharmacology 20100201

• Current treatment options in smoking cessation.

  Hospital practice (1995) 20100201

• Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier.

  Bioorganic & medicinal chemistry letters 20100115

• Antinociceptive effect of the cannabinoid agonist, WIN 55,212-2, in the orofacial and temporomandibular formalin tests.

  European journal of pain (London, England) 20100101

• Rimonabant (SR141716) has no effect on alcohol self-administration or endocrine measures in nontreatment-seeking heavy alcohol drinkers.

  Psychopharmacology 20100101

• Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.

  Oncology reports 20100101

• Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.

  PloS one 20100101

• The cannabinoid receptor agonist WIN 55,212-2 inhibits antigen-induced plasma extravasation in guinea pig airways.

  International archives of allergy and immunology 20100101

• Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists.

  Current medicinal chemistry 20100101

• Effect of the CB1 cannabinoid agonist WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference in mice.

  Behavioral and brain functions : BBF 20100101

• [Simultaneous determination of rimonabant and orlistat illegally added in the weight-loss functional foods by high performance liquid chromatography-tandem mass spectrometry].

  Se pu = Chinese journal of chromatography 20100101

• Endocannabinoids and their role in fatty liver disease.

  Digestive diseases (Basel, Switzerland) 20100101

• Validated stability-indicating RP-HPLC method for the determination of rimonabant in a pharmaceutical dosage form.

  Journal of AOAC International 20100101

• The endocannabinoid system links gut microbiota to adipogenesis.

  Molecular systems biology 20100101

• A method for parallel solid-phase synthesis of iodinated analogs of the cannabinoid receptor type I (CB₁) inverse agonist rimonabant.

  Methods in enzymology 20100101

• Rimonabant attenuates sensitization, cross-sensitization and cross-reinstatement of place preference induced by nicotine and ethanol.

  Pharmacological reports : PR 20100101

• Sub-chronic administration of rimonabant causes loss of antidepressive activity and decreases doublecortin immunoreactivity in the mouse hippocampus.

  Neuroscience letters 20091225

• Central cannabinoid 1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area.

  Shock (Augusta, Ga.) 20091201

• The CB1 antagonist rimonabant (SR141716) blocks cue-induced reinstatement of cocaine seeking and other context and extinction phenomena predictive of relapse.

  Drug and alcohol dependence 20091201

• Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.

  Journal of cardiovascular pharmacology and therapeutics 20091201

• Signaling pathways from cannabinoid receptor-1 activation to inhibition of N-methyl-D-aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion neurons.

  The Journal of pharmacology and experimental therapeutics 20091201

• Monoacylglycerol lipase limits the duration of endocannabinoid-mediated depolarization-induced suppression of excitation in autaptic hippocampal neurons.

  Molecular pharmacology 20091201

• Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?

  Cardiovascular research 20091201

• Pharmacotherapy for obesity.

  British journal of clinical pharmacology 20091201

• Cannabinoids prevent the opposite regulation of astroglial connexin43 hemichannels and gap junction channels induced by pro-inflammatory treatments.

  Journal of neurochemistry 20091201

• Central cannabinoid signaling mediating food intake: a pharmacological-challenge magnetic resonance imaging and functional histology study in rat.

  Neuroscience 20091110

• Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice.

  Neuroscience letters 20091106

• The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.

  Behavioural brain research 20091105

• The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction.

  Basic research in cardiology 20091101

• Fatty acid amide hydrolase (FAAH) knockout mice exhibit enhanced acquisition of an aversive, but not of an appetitive, Barnes maze task.

  Neurobiology of learning and memory 20091101

• Effects of cannabinoid drugs on the reinforcing properties of food in gestationally undernourished rats.

  Pharmacology, biochemistry, and behavior 20091101

• Prosocial effects of nicotine and ethanol in adolescent rats through partially dissociable neurobehavioral mechanisms.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20091101

• Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.

  Drug and alcohol dependence 20091101

• FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats.

  Pharmacology, biochemistry, and behavior 20091101

• Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet.

  American journal of physiology. Endocrinology and metabolism 20091101

• CB1 antagonists for obesity--what lessons have we learned from rimonabant?

  Nature reviews. Endocrinology 20091101

• Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices.

  British journal of pharmacology 20091101

• Involvement of adipokines in rimonabant-mediated insulin sensitivity in ob/ob mice.

  The Journal of pharmacy and pharmacology 20091101

• Characterization of the endocannabinoid system in human neuronal cells and proteomic analysis of anandamide-induced apoptosis.

  The Journal of biological chemistry 20091023

• Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands.

  The Journal of biological chemistry 20091023

• A method for parallel solid-phase synthesis of iodinated analogues of the CB1 receptor inverse agonist rimonabant.

  Organic letters 20091015

• The endocannabinoid system: potential for reducing cardiometabolic risk.

  Obesity (Silver Spring, Md.) 20091001

• The CB1 antagonist rimonabant decreases insulin hypersecretion in rat pancreatic islets.

  Obesity (Silver Spring, Md.) 20091001

• Sex and cannabinoid CB1 genotype differentiate palatable food and cocaine self-administration behaviors in mice.

  Behavioural pharmacology 20091001

• Rimonabant for the treatment of overweight and obese people.

  Health technology assessment (Winchester, England) 20091001

• Bioisosteric replacement of the hydrazide pharmacophore of the cannabinoid-1 receptor antagonist SR141716A. Part I: potent, orally-active 1,4-disubstituted imidazoles.

  Bioorganic & medicinal chemistry letters 20090915

• Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats.

  Behavioural brain research 20090914

• Cannabinoid receptor 1 signalling dampens activity and mitochondrial transport in networks of enteric neurones.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20090901

• Pre-exposure to environmental cues predictive of food availability elicits hypothalamic-pituitary-adrenal axis activation and increases operant responding for food in female rats.

  Addiction biology 20090901

• Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20090901

• Rimonabant inhibits human colon cancer cell growth and reduces the formation of precancerous lesions in the mouse colon.

  International journal of cancer 20090901

• Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade.

  Psychopharmacology 20090901

• Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats.

  Psychopharmacology 20090901

• Age-dependent effects of the cannabinoid CB1 antagonist SR141716A on food intake, body weight change, and pruritus in rats.

  Psychopharmacology 20090901

• Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.

  International journal of obesity (2005) 20090901

• Rimonabant induces partial seizures in a patient with a history of generalized epilepsy.

  Epilepsia 20090901

• Beneficial effect of a chronic treatment with rimonabant on pancreatic function and beta-cell morphology in Zucker Fatty rats.

  European journal of pharmacology 20090815

• Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization.

  Science (New York, N.Y.) 20090807

• Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia.

  Gut 20090801

• Blood, adipose tissue and brain levels of the cannabinoid ligands WIN-55,212 and SR-141716A after their intraperitoneal injection in mice: compound-specific and area-specific distribution within the brain.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20090801

• Hippocampal CB(1) receptors mediate the memory impairing effects of Delta(9)-tetrahydrocannabinol.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090801

• Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.

  Obesity (Silver Spring, Md.) 20090801

• Depolarizing GABAergic synaptic input triggers endocannabinoid-mediated retrograde synaptic signaling.

  Synapse (New York, N.Y.) 20090801

• CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.

  The Journal of pharmacology and experimental therapeutics 20090801

• Discriminative stimulus properties of delta9-tetrahydrocannabinol (THC) in C57Bl/6J mice.

  European journal of pharmacology 20090801

• Discovery and functional evaluation of diverse novel human CB(1) receptor ligands.

  Bioorganic & medicinal chemistry letters 20090801

• Long-term effects of weight-reducing drugs in hypertensive patients.

  The Cochrane database of systematic reviews 20090708

• Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis.

  Gastroenterology 20090701

• Effect of antiobesity medications in patients with type 2 diabetes mellitus.

  Diabetes, obesity & metabolism 20090701

• Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers.

  Psychopharmacology 20090701

• Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model.

  Epilepsy research 20090701

• Hit-to-lead optimization of pyrrolo[1,2-a]quinoxalines as novel cannabinoid type 1 receptor antagonists.

  Bioorganic & medicinal chemistry letters 20090701

• Effects of chronic treatment with the CB1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats.

  Obesity (Silver Spring, Md.) 20090701

• End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.

  Nature reviews. Drug discovery 20090701

• Rimonabant may induce atrial fibrillation.

  BMJ (Clinical research ed.) 20090612

• Modulation of anxiety by acute blockade and genetic deletion of the CB(1) cannabinoid receptor in mice together with biogenic amine changes in the forebrain.

  Behavioural brain research 20090608

• Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice.

  Psychopharmacology 20090601

• Depolarization-induced release of endocannabinoids by murine dorsal motor nucleus of the vagus nerve neurons differentially regulates inhibitory and excitatory neurotransmission.

  Neuropharmacology 20090601

• Rimonabant prevents additional accumulation of visceral and subcutaneous fat during high-fat feeding in dogs.

  American journal of physiology. Endocrinology and metabolism 20090601

• Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.

  The AAPS journal 20090601

• The endocannabinoid system: a new pharmacological target for obesity treatment?

  Neuroscience bulletin 20090601

• Involvement of hypothalamic peptides in the anorectic action of the CB receptor antagonist rimonabant (SR 141716).

  The European journal of neuroscience 20090601

• [Current and future medical drugs for smoking cessation].

  Laryngo- rhino- otologie 20090601

• The psychiatric side-effects of rimonabant.

  Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 20090601

• Effects of the cannabinoid receptor ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated plus maze test.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20090601

• The structure of Rimonabant in the solid state and in solution: an experimental and theoretical study.

  European journal of medicinal chemistry 20090501

• Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice.

  Psychopharmacology 20090501

• Cannabinoid receptor-1 blockade attenuates acute pancreatitis in obesity by an adiponectin mediated mechanism.

  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 20090501

• Development and validation of a high-performance liquid chromatographic method for bioanalytical application with rimonabant.

  Journal of pharmaceutical and biomedical analysis 20090501

• Hair growth stimulator property of thienyl substituted pyrazole carboxamide derivatives as a CB1 receptor antagonist with in vivo antiobesity effect.

  Bioorganic & medicinal chemistry letters 20090501

• [2008: the end of rimonabant's story].

  Annales pharmaceutiques francaises 20090501

• Opioid, cannabinoid CB1 and NOP receptors do not mediate APAP-induced hypothermia in rats.

  Pharmacology, biochemistry, and behavior 20090501

• Rimonabant affects cyclosporine a, but not tacrolimus pharmacokinetics in renal transplant recipients.

  Transplantation 20090427

• The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew).

  Physiology & behavior 20090420

• CB1 cannabinoid receptor participates in the vascular hyporeactivity resulting from hemorrhagic shock in rats.

  Chinese medical journal 20090420

• Synthesis and structure-activity relationship of novel diarylpyrazole imide analogues as CB1 cannabinoid receptor ligands.

  Bioorganic & medicinal chemistry 20090415

• A role for the endocannabinoid system in the increased motivation for cocaine in extended-access conditions.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090415

• Nonlinear turnover models for systems with physiological limits.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090411

• Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog.

  Psychopharmacology 20090401

• Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.

  Psychopharmacology 20090401

• Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation.

  Psychopharmacology 20090401

• Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle.

  Diabetologia 20090401

• Adiponectin is required to mediate rimonabant-induced improvement of insulin sensitivity but not body weight loss in diet-induced obese mice.

  American journal of physiology. Regulatory, integrative and comparative physiology 20090401

• Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.

  International review of psychiatry (Abingdon, England) 20090401

• Impairments in endocannabinoid signaling and depressive illness.

  JAMA 20090318

• Localization and phenotypic characterization of brainstem neurons activated by rimonabant and WIN55,212-2.

  Brain research bulletin 20090316

• Endocannabinoids mediate acute fear adaptation via glutamatergic neurons independently of corticotropin-releasing hormone signaling.

  Genes, brain, and behavior 20090301

• Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial.

  Arteriosclerosis, thrombosis, and vascular biology 20090301

• CB1 receptor knockout mice are hyporesponsive to the behavior-stimulating actions of d-amphetamine: role of mGlu5 receptors.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20090301

• ADAGIO-Lipids gives promises but faces the setbacks.

  Arteriosclerosis, thrombosis, and vascular biology 20090301

• A CB(2) receptor agonist, A-836339, modulates wide dynamic range neuronal activity in neuropathic rats: contributions of spinal and peripheral CB(2) receptors.

  Neuroscience 20090218

• Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome.

  Clinical endocrinology 20090201

• Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant.

  Drug discovery today 20090201

• Blockade of the endocannabinoid system for the reduction of cardiometabolic risk factors.

  Obesity (Silver Spring, Md.) 20090201

• The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure.

  Obesity (Silver Spring, Md.) 20090201

• Current pharmacotherapeutic concepts for the treatment of obesity in adults.

  Therapeutic advances in cardiovascular disease 20090201

• A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain.

  Addiction (Abingdon, England) 20090201

• Trial comes too late as psychiatric side effects end hope for rimonabant.

  Addiction (Abingdon, England) 20090201

• The endocannabinoid system: a promising target for the management of type 2 diabetes.

  Current protein & peptide science 20090201

• Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.

  Best practice & research. Clinical endocrinology & metabolism 20090201

• Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.

  Best practice & research. Clinical endocrinology & metabolism 20090201

• The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism.

  International journal of cardiology 20090124

• Interventions for preventing weight gain after smoking cessation.

  The Cochrane database of systematic reviews 20090121

• Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways.

  The Journal of biological chemistry 20090116

• Glucocorticoids regulate glutamate and GABA synapse-specific retrograde transmission via divergent nongenomic signaling pathways.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20090114

• Non-opioid antinociception produced by brain stem injections of improgan: significance of local, but not cross-regional, cannabinoid mechanisms.

  Brain research 20090109

• [Nutrition-obesity. Rimonabant and cardiovascular risk factors].

  Revue medicale suisse 20090107

• Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages.

  Circulation 20090106

• Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew.

  Behavioural brain research 20090103

• Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents.

  Neuroscience letters 20090102

• Functional interactions between endocannabinoid and CCK neurotransmitter systems may be critical for extinction learning.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20090101

• Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice.

  Arteriosclerosis, thrombosis, and vascular biology 20090101

• Cannabinoid-1 (CB1) receptors regulate colonic propulsion by acting at motor neurons within the ascending motor pathways in mouse colon.

  American journal of physiology. Gastrointestinal and liver physiology 20090101

• Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans.

  British journal of pharmacology 20090101

• Post-ischemic brain damage: the endocannabinoid system in the mechanisms of neuronal death.

  The FEBS journal 20090101

• Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns?

  Arteriosclerosis, thrombosis, and vascular biology 20090101

• Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).

  Clinical endocrinology 20090101

• Recent advances in obesity pharmacotherapy.

  Current clinical pharmacology 20090101

• Pleiotropic effects of rimonabant: clinical implications.

  Current pharmaceutical design 20090101

• Withdrawal of Rimonabant--walking the tightrope of 21st century pharmaceutical regulation?

  Current drug safety 20090101

• Effect of blockage of the endocannabinoid system by CB(1) antagonism on cardiovascular risk.

  Pharmacological reports : PR 20090101

• [From a crisis to another...Pharmaceutical industry--economics].

  Revue medicale de Liege 20090101

• Obesity, the endocannabinoid system, and bias arising from pharmaceutical sponsorship.

  PloS one 20090101

• Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.

  Pharmacological reports : PR 20090101

• [Drug treatment of obesity].

  Revue medicale de Bruxelles 20090101

• Role of the endocannabinoid system in abdominal obesity and the implications for cardiovascular risk.

  Cardiology 20090101

• Cannabinoid receptor CB1 antagonists state of the art and challenges.

  Vitamins and hormones 20090101

• Endocannabinoid system and fear conditioning.

  Vitamins and hormones 20090101

• Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.

  BMC gastroenterology 20090101

• Melancholic features related to rimonabant.

  General hospital psychiatry 20090101

• Comparison of rimonabant and sibutramine treatment effects on food compulsion in rats.

  Acta cirurgica brasileira 20090101

• [Adipose tissue inflammation and atherosclerosis].

  Kardiologiia 20090101

• The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury.

  Clinical neurosurgery 20090101

• Drug addiction.

  Current topics in behavioral neurosciences 20090101

• Feeding disorders and obesity.

  Current topics in behavioral neurosciences 20090101

• Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation.

  Biochemical and biophysical research communications 20081226

• Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20081217

• Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant.

  European journal of medicinal chemistry 20081201

• A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.

  Clinical endocrinology 20081201

• Exploring the binding features of rimonabant analogues and acyclic CB1 antagonists: docking studies and QSAR analysis.

  Journal of molecular modeling 20081201

• Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20081201

• Antipsychotic-induced alterations in CB1 receptor-mediated G-protein signaling and in vivo pharmacology in rats.

  Neuropharmacology 20081201

• The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase.

  Molecular pharmacology 20081201

• Auditory gating in rat hippocampus and medial prefrontal cortex: effect of the cannabinoid agonist WIN55,212-2.

  Neuropharmacology 20081201

• CB(1) receptor antagonism: biological basis for metabolic effects.

  Drug discovery today 20081201

• Cost-effectiveness of pharmacological anti-obesity treatments: a systematic review.

  International journal of obesity (2005) 20081201

• Differential response to a selective cannabinoid receptor antagonist (SR141716: rimonabant) in female mice from lines selectively bred for high voluntary wheel-running behaviour.

  Behavioural pharmacology 20081201

• End of the line for cannabinoid receptor 1 as an anti-obesity target?

  Nature reviews. Drug discovery 20081201

• Delta-9-tetrahydrocannabinol differently affects striatal c-Fos expression following haloperidol or clozapine administration.

  European journal of pharmacology 20081119

• The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain.

  Neuroscience 20081111

• Constitutive activity at the cannabinoid CB1 receptor is required for behavioral response to noxious chemical stimulation of TRPV1: antinociceptive actions of CB1 inverse agonists.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20081105

• Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081101

• Enhancement of endocannabinoid neurotransmission through CB1 cannabinoid receptors counteracts the reinforcing and psychostimulant effects of cocaine.

  The international journal of neuropsychopharmacology 20081101

• Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.

  Pharmacology, biochemistry, and behavior 20081101

• SERENADE: the Study Evaluating Rimonabant Efficacy in Drug-naive Diabetic Patients: effects of monotherapy with rimonabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naive type 2 diabetes.

  Diabetes care 20081101

• N-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipase.

  The Journal of pharmacology and experimental therapeutics 20081101

• Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.

  Diabetes 20081101

• Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.

  Obesity (Silver Spring, Md.) 20081101

• [New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].

  La Revue de medecine interne 20081101

• Ethanol self-administration is regulated by CB1 receptors in the nucleus accumbens and ventral tegmental area in alcohol-preferring AA rats.

  Alcoholism, clinical and experimental research 20081101

• Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons.

  Journal of neurochemistry 20081101

• Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study.

  Expert opinion on pharmacotherapy 20081101

• Current and emerging therapies in nonalcoholic fatty liver disease.

  Seminars in liver disease 20081101

• Differential endocannabinoid regulation of extinction in appetitive and aversive Barnes maze tasks.

  Learning & memory (Cold Spring Harbor, N.Y.) 20081101

• Rimonabant for the treatment of obesity.

  Recent patents on cardiovascular drug discovery 20081101

• Context-specific reversal of cocaine sensitization by the CB1 cannabinoid receptor antagonist rimonabant.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20081001

• N-arachidonylethanolamide-induced increase in aqueous humor outflow facility.

  Investigative ophthalmology & visual science 20081001

• An endocannabinoid signaling system modulates anxiety-like behavior in male Syrian hamsters.

  Psychopharmacology 20081001

• Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A).

  Neuropharmacology 20081001

• Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

  Naunyn-Schmiedeberg's archives of pharmacology 20081001

• Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?

  Nature clinical practice. Cardiovascular medicine 20081001

• Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis.

  The American journal of pathology 20081001

• Effects of rimonabant on behavior maintained by progressive ratio schedules of sucrose reinforcement in obese Zucker (fa/fa) rats.

  Behavioural pharmacology 20081001

• Is rimonabant efficacious and safe in the treatment of obesity?

  Expert opinion on pharmacotherapy 20081001

• [Sleep disorders associated with treatment with rimonabant].

  Revista de neurologia 20081001

• Recent advances in the management of type 2 diabetes mellitus: a review.

  Postgraduate medical journal 20081001

• Pharmacotherapy for smoking cessation.

  Therapeutic advances in respiratory disease 20081001

• [Association of obesity and depression].

  Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology 20081001

• Endocannabinoid system and cardio-metabolic risk.

  The Medical journal of Malaysia 20081001

• Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists.

  Organic & biomolecular chemistry 20080921

• Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists.

  Journal of medicinal chemistry 20080911

• Attenuation of cue-induced heroin-seeking behavior by cannabinoid CB1 antagonist infusions into the nucleus accumbens core and prefrontal cortex, but not basolateral amygdala.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080901

• The effect of cannabinoid CB(1) receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats.

  Alcohol (Fayetteville, N.Y.) 20080901

• Leptin receptor deficiency is associated with upregulation of cannabinoid 1 receptors in limbic brain regions.

  Synapse (New York, N.Y.) 20080901

• Reversal of visceral adiposity in candy-diet fed female Wistar rats by the CB1 receptor antagonist rimonabant.

  International journal of obesity (2005) 20080901

• Depression and weight loss: opposite outcome for surgery and rimonabant?

  Obesity reviews : an official journal of the International Association for the Study of Obesity 20080901

• Determination of rimonabant in human plasma and hair by liquid chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080901

• Rimonabant and depression.

  Pharmacopsychiatry 20080901

• [CB1 receptor inhibition and glucose metabolism: role of rimonabant in type 2 diabetes].

  Revue medicale suisse 20080827

• [Rimonabant helps in overweight patients with multiple cardiovascular risk factors such as type 2 diabetes].

  Revue medicale suisse 20080827

• The cannabinoid CB(1) receptor antagonist CE prolongs spatial memory duration in a rat delayed radial arm maze memory task.

  European journal of pharmacology 20080820

• The CB1 receptor antagonist, SR141716A, prevents high-frequency stimulation-induced reduction of feedback inhibition in the rat dentate gyrus following perforant path stimulation in vivo.

  Brain research 20080805

• The endogenous cannabinoid system modulates nicotine reward and dependence.

  The Journal of pharmacology and experimental therapeutics 20080801

• Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes.

  Diabetes 20080801

• Endocannabinoid- and mGluR5-dependent short-term synaptic depression in an isolated neuron/bouton preparation from the hippocampal CA1 region.

  Journal of neurophysiology 20080801

• CB(1) cannabinoid receptor activation dose dependently modulates neuronal activity within caudal but not rostral song control regions of adult zebra finch telencephalon.

  Psychopharmacology 20080801

• Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice.

  Synapse (New York, N.Y.) 20080801

• The CB1 endocannabinoid system modulates adipocyte insulin sensitivity.

  Obesity (Silver Spring, Md.) 20080801

• Aqueous humor outflow effects of 2-arachidonylglycerol.

  Experimental eye research 20080801

• Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.

  European journal of pharmacology 20080728

• Delta(9)-tetrahydrocannabinol prolongs the immobility time in the mouse forced swim test: involvement of cannabinoid CB(1) receptor and serotonergic system.

  European journal of pharmacology 20080728

• Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests.

  European journal of pharmacology 20080728

• Rimonabant and progression of atherosclerosis in obese persons.

  JAMA 20080716

• Facile synthesis, ex-vivo and in vitro screening of 3-sulfonamide derivative of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide (SR141716) a potent CB1 receptor antagonist.

  Bioorganic & medicinal chemistry letters 20080715

• Cannabinoid agonists differentially substitute for the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice.

  Psychopharmacology 20080701

• Rimonabant blocks the expression but not the development of locomotor sensitization to nicotine in rats.

  Psychopharmacology 20080701

• Cat odour-induced anxiety--a study of the involvement of the endocannabinoid system.

  Psychopharmacology 20080701

• Hippocampal endocannabinoids inhibit spatial learning and limit spatial memory in rats.

  Psychopharmacology 20080701

• Endocannabinoids modulate encoding of sequential memory in the rat hippocampus.

  Psychopharmacology 20080701

• Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats.

  Psychopharmacology 20080701

• Reply to the letter to the editor 'Long-term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer'.

  International journal of cancer 20080701

• Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study.

  European heart journal 20080701

• Cannabinoid-1 receptor antagonists reduce caloric intake by decreasing palatable diet selection in a novel dessert protocol in female rats.

  American journal of physiology. Regulatory, integrative and comparative physiology 20080701

• Rimonabant in rats with a metabolic syndrome: good news after the depression.

  British journal of pharmacology 20080701

• Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice.

  British journal of pharmacology 20080701

• The cannabinoid receptor-1 antagonist rimonabant inhibits platelet activation and reduces pro-inflammatory chemokines and leukocytes in Zucker rats.

  British journal of pharmacology 20080701

• Short- and long-term effects of cannabinoids on the extinction of contextual fear memory in rats.

  Neurobiology of learning and memory 20080701

• Inhibitors of cannabinoid receptors and glucose metabolism.

  Current opinion in clinical nutrition and metabolic care 20080701

• The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.

  European heart journal 20080701

• The element of surprise.

  Nature medicine 20080701

• Soothing the seizures of children.

  Nature medicine 20080701

• Acute effects of the cannabinoid receptor agonist WIN55212-2 on dopamine release in rat: an in vivo electrochemical study.

  The Chinese journal of physiology 20080630

• Conformationally constrained analogues of N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716): design, synthesis, computational analysis, and biological evaluations.

  Journal of medicinal chemistry 20080626

• The cannabinoid CB1 receptor antagonist rimonabant dose-dependently inhibits memory recall in the passive avoidance task in domestic chicks (Gallus domesticus).

  Brain research bulletin 20080615

• Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.

  Neuroscience letters 20080613

• Endogenous opioids and cannabinoids: system interactions in the regulation of appetite, grooming and scratching.

  Physiology & behavior 20080609

• Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice.

  The pharmacogenomics journal 20080601

• Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: experiments with self-administration and brain-stimulation reward in rats.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080601

• Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20080601

• The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20080601

• Aminopyrazine CB1 receptor inverse agonists.

  Bioorganic & medicinal chemistry letters 20080601

• Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.

  Journal of clinical psychopharmacology 20080601

• The role of CB1 receptors in psychostimulant addiction.

  Addiction biology 20080601

• Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.

  Addiction biology 20080601

• Pharmacotherapy for obesity in menopausal women.

  Menopause international 20080601

• Locomotor effects of morphine or alcohol in mice after a repeated treatment with the cannabinoid agonist HU 210.

  European journal of pharmacology 20080531

• [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].

  Praxis 20080528

• Liquid chromatography tandem mass spectrometry method for the quantification of rimonabant, a CB1 receptor antagonist, in human plasma.

  Biomedical chromatography : BMC 20080501

• Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.

  International journal of obesity (2005) 20080501

• Effects of a Cannabinoid1 receptor antagonist and Serotonin2C receptor agonist alone and in combination on motivation for palatable food: a dose-addition analysis study in mice.

  The Journal of pharmacology and experimental therapeutics 20080501

• Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.

  Endocrinology 20080501

• First in vivo evidence for a functional interaction between chemokine and cannabinoid systems in the brain.

  The Journal of pharmacology and experimental therapeutics 20080501

• The phytocannabinoid Delta(9)-tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum.

  British journal of pharmacology 20080501

• CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.

  Neuropharmacology 20080501

• Cytochrome P-450 metabolites of 2-arachidonoylglycerol play a role in Ca2+-induced relaxation of rat mesenteric arteries.

  American journal of physiology. Heart and circulatory physiology 20080501

• A saturated N-acylethanolamine other than N-palmitoyl ethanolamine with anti-inflammatory properties: a neglected story..

  Journal of neuroendocrinology 20080501

• Endocannabinoids, blood pressure and the human heart.

  Journal of neuroendocrinology 20080501

• Blood pressure lowering effects of rimonabant in obesity-related hypertension.

  Journal of neuroendocrinology 20080501

• Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.

  Journal of neuroendocrinology 20080501

• Cannabinoid type 1 receptor: another arrow in the adipocytes' bow.

  Journal of neuroendocrinology 20080501

• CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.

  Journal of neuroendocrinology 20080501

• The endocannabinoid system and the control of glucose homeostasis.

  Journal of neuroendocrinology 20080501

• The challenge of treating obesity: the endocannabinoid system as a potential target.

  Journal of the American Dietetic Association 20080501

• Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats.

  Behavioural pharmacology 20080501

• [Treatment of type 2 diabetes with new oral antihyperglycaemic drugs].

  MMW Fortschritte der Medizin 20080501

• [Rimonabant. Risk of depression has not been finally clarified].

  Medizinische Monatsschrift fur Pharmazeuten 20080501

• Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors.

  The Journal of biological chemistry 20080425

• Long term cannabinoid receptor (CB1) blockade in obesity: implications for the development of colorectal cancer.

  International journal of cancer 20080415

• Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

  JAMA 20080402

• The hope and fear of rimonabant.

  JAMA 20080402

• [The endocannabinoid system].

  Praxis 20080402

• Bidirectional cannabinoid modulation of social behavior in adolescent rats.

  Psychopharmacology 20080401

• Smoking cessation 2008.

  IDrugs : the investigational drugs journal 20080401

• Stress-induced analgesia in mice: evidence for interaction between endocannabinoids and cholecystokinin.

  The European journal of neuroscience 20080401

• Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.

  Current atherosclerosis reports 20080401

• [Residual risk in cardiovascular prevention].

  Giornale italiano di cardiologia (2006) 20080401

• [Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy].

  Giornale italiano di cardiologia (2006) 20080401

• [Pharmacological therapy of obesity].

  Giornale italiano di cardiologia (2006) 20080401

• Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.

  Physiology & behavior 20080318

• Cannabinoid CB(1) receptor activation modulates spontaneous contractile activity in mouse ileal longitudinal muscle.

  European journal of pharmacology 20080317

• Trimethylaluminium mediated amide bond formation in a continuous flow microreactor as key to the synthesis of rimonabant and efaproxiral.

  Chemical communications (Cambridge, England) 20080307

• Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells.

  British journal of pharmacology 20080301

• Alcohol inhibits spontaneous activity of basolateral amygdala projection neurons in the rat: involvement of the endocannabinoid system.

  Alcoholism, clinical and experimental research 20080301

• Cannabinoid receptor 2 (CB2) mediates immunoglobulin class switching from IgM to IgE in cultures of murine-purified B lymphocytes.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20080301

• Determination of endocannabinoid receptor antagonist SR141716 (rimonabant) in plasma by liquid chromatograph tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080301

• Oral administration of the antiobesity drugs, sibutramine and rimonabant, increases acetylcholine efflux selectively in the medial prefrontal cortex of the rat.

  Molecular psychiatry 20080301

• Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors.

  Cell metabolism 20080301

• Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver.

  Cell metabolism 20080301

• Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence.

  Expert review of neurotherapeutics 20080301

• [Prescription of rimonabant in the early stage of pregnancy?].

  Medizinische Monatsschrift fur Pharmazeuten 20080301

• [Rimonabant (Acomplia)].

  Journal de pharmacie de Belgique 20080301

• [The endocannabinoid system and treatment of obesity].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20080227

• Efficacy and safety of the weight-loss drug rimonabant.

  Lancet (London, England) 20080216

• Efficacy and safety of the weight-loss drug rimonabant.

  Lancet (London, England) 20080216

• Involvement of subthalamic nucleus in the stimulatory effect of Delta(9)-tetrahydrocannabinol on dopaminergic neurons.

  Neuroscience 20080206

• Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward.

  Biological psychiatry 20080201

• Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice.

  Diabetes, obesity & metabolism 20080201

• Cannabinoids stimulate prostaglandin production by human gestational tissues through a tissue- and CB1-receptor-specific mechanism.

  American journal of physiology. Endocrinology and metabolism 20080201

• Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results.

  Journal of hypertension 20080201

• Topical WIN55212-2 alleviates intraocular hypertension in rats through a CB1 receptor mediated mechanism of action.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20080201

• Bioisosteric replacement of dihydropyrazole of 4S-(-)-3-(4-chlorophenyl)-N-methyl-N'-[(4-chlorophenyl)-sulfonyl]-4-phenyl-4,5-dihydro-1H-pyrazole-1-caboxamidine (SLV-319) a potent CB1 receptor antagonist by imidazole and oxazole.

  Bioorganic & medicinal chemistry letters 20080201

• Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.

  Diabetes care 20080201

• Is weight loss beneficial for reduction of morbidity and mortality? What is the controversy about?

  Diabetes care 20080201

• Rimonabant: new data and emerging experience.

  Current atherosclerosis reports 20080201

• Endocannabinoid system overactivity and the metabolic syndrome: prospects for treatment.

  Current diabetes reports 20080201

• Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex.

  Neuroscience letters 20080124

• Delta 9-tetrahydrocannabinol-induced catalepsy-like immobilization is mediated by decreased 5-HT neurotransmission in the nucleus accumbens due to the action of glutamate-containing neurons.

  Neuroscience 20080124

• The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.

  Neuropharmacology 20080101

• Methanandamide activation of a novel current in mouse trigeminal ganglion sensory neurons in vitro.

  Neuropharmacology 20080101

• Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells.

  Neuropharmacology 20080101

• Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.

  Neuropharmacology 20080101

• Cross-sensitization and cross-tolerance between exogenous cannabinoid antinociception and endocannabinoid-mediated stress-induced analgesia.

  Neuropharmacology 20080101

• Long-term cognitive deficits induced by a single, extremely low dose of tetrahydrocannabinol (THC): behavioral, pharmacological and biochemical studies in mice.

  Pharmacology, biochemistry, and behavior 20080101

• Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1.

  Neuropharmacology 20080101

• Antidepressant-like behavioral effects of impaired cannabinoid receptor type 1 signaling coincide with exaggerated corticosterone secretion in mice.

  Psychoneuroendocrinology 20080101

• Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.

  Journal of neuroimmunology 20080101

• [Pharmacotherapy of obesity].

  Der Internist 20080101

• An update on therapeutics for tobacco dependence.

  Expert opinion on pharmacotherapy 20080101

• Role of the endocannabinoid system in metabolic control.

  Current opinion in nephrology and hypertension 20080101

• Cost-utility analysis of rimonabant in the treatment of obesity.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20080101

• Obesity: a review of pathogenesis and management strategies.

  Canadian journal of gastroenterology = Journal canadien de gastroenterologie 20080101

• Role of the endocannabinoid system in energy balance regulation and obesity.

  Frontiers of hormone research 20080101

• Emerging concepts in the medical and surgical treatment of obesity.

  Frontiers of hormone research 20080101

• [Correct prescription of Acomplia (rimonabant) is assured by knowledge].

  Lakartidningen 20080101

• [Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].

  Revue medicale de Liege 20080101

• The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system.

  PloS one 20080101

• Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis.

  Arthritis research & therapy 20080101

• Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status.

  Drugs 20080101

• Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.

  Chemical record (New York, N.Y.) 20080101

• STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.

  Cardiovascular journal of Africa 20080101

• Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.

  Angiology 20080101

• [Raising HDL cholesterol: which is the best strategy?].

  Revista da Associacao Medica Brasileira (1992) 20080101

• [Role of cannabinoid receptors in regulation of cardiac tolerance to ischemia and reperfusion].

  Izvestiia Akademii nauk. Seriia biologicheskaia 20080101

• Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics.

  Cardiovascular journal of Africa 20080101

• Different transcriptional control of metabolism and extracellular matrix in visceral and subcutaneous fat of obese and rimonabant treated mice.

  PloS one 20080101

• The endocannabinoid system as a target for obesity treatment.

  Clinical cornerstone 20080101

• CB1 cannabinoid receptor inhibition: promising approach for heart failure?

  Congestive heart failure (Greenwich, Conn.) 20080101

• Smoking cessation in cardiovascular patients.

  Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 20080101

• New therapeutic approaches in type 2 diabetes.

  Acta clinica Belgica 20080101

• Psychosis following anti-obesity treatment with rimonabant.

  Obesity facts 20080101

• Potentiation of electrical and chemical synaptic transmission mediated by endocannabinoids.

  Neuron 20071220

• [Still questions around the slimming agent rimobant. Not approved in USA because of the risk of mental adverse effects].

  Lakartidningen 20071219

• Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: efficacy.

  The American journal of cardiology 20071217

• Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.

  The American journal of cardiology 20071217

• Effect of cannabinoid CB1 receptor antagonist SR141716A and CB1 receptor knockout on cue-induced reinstatement of Ensure and corn-oil seeking in mice.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20071201

• Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro.

  Journal of molecular medicine (Berlin, Germany) 20071201

• The uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist memantine prolongs spatial memory in a rat delayed radial-arm maze memory task.

  European journal of pharmacology 20071201

• Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity.

  Bioorganic & medicinal chemistry 20071201

• Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.

  Kidney international 20071201

• Functional blockage of the cannabinoid receptor type 1 evokes a kappa-opiate-dependent analgesia.

  Journal of neurochemistry 20071201

• Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor.

  Journal of hypertension 20071201

• C-terminal truncated cannabinoid receptor 1 coexpressed with G protein trimer in Sf9 cells exists in a precoupled state and shows constitutive activity.

  The FEBS journal 20071201

• Cannabinoid-induced tolerance is associated with a CB1 receptor G protein coupling switch that is prevented by ultra-low dose rimonabant.

  Behavioural pharmacology 20071201

• CB1 receptor-mediated control of the release of endocannabinoids (as assessed by microdialysis coupled with LC/MS) in the rat hypothalamus.

  The European journal of neuroscience 20071201

• Cannabinoid-1 receptor antagonists in type-2 diabetes.

  Best practice & research. Clinical endocrinology & metabolism 20071201

• Pharmacotherapy for obesity.

  Current atherosclerosis reports 20071201

• Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.

  Journal of medicinal chemistry 20071129

• [Antiobesity drugs--new limitations].

  Revue medicale suisse 20071128

• [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].

  Nederlands tijdschrift voor geneeskunde 20071124

• [New drugs; rimonabant].

  Nederlands tijdschrift voor geneeskunde 20071124

• Depression and anxiety with rimonabant.

  Lancet (London, England) 20071117

• Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.

  Lancet (London, England) 20071117

• Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.

  European journal of pharmacology 20071114

• Cannabinoid CB(1) receptor and gastric acid secretion.

  Digestive diseases and sciences 20071101

• Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

  British journal of pharmacology 20071101

• PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats.

  British journal of pharmacology 20071101

• Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users.

  Psychopharmacology 20071101

• Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats.

  Psychopharmacology 20071101

• Significance of cannabinoid CB1 receptors in improgan antinociception.

  The journal of pain : official journal of the American Pain Society 20071101

• The endogenous cannabinoid anandamide inhibits cromakalim-activated K+ currents in follicle-enclosed Xenopus oocytes.

  The Journal of pharmacology and experimental therapeutics 20071101

• Management of obesity in patients with peripheral arterial disease.

  European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20071101

• The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation.

  British journal of pharmacology 20071101

• Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.

  British journal of pharmacology 20071101

• Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.

  Pediatric research 20071101

• Lack of depolarization-induced suppression of inhibition (DSI) in layer 2/3 interneurons that receive cannabinoid-sensitive inhibitory inputs.

  Journal of neurophysiology 20071101

• The genetic versus pharmacological invalidation of the cannabinoid CB(1) receptor results in differential effects on 'non-associative' memory and forebrain monoamine concentrations in mice.

  Neurobiology of learning and memory 20071101

• Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl)benzamide (VSN16) in the rat.

  British journal of pharmacology 20071101

• Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619.

  British journal of pharmacology 20071101

• Endocannabinoid system and cardiometabolic risk.

  Clinical pharmacology and therapeutics 20071101

• Effects of AM1346, a high-affinity CB1 receptor selective anandamide analog, on open-field behavior in rats.

  Behavioural pharmacology 20071101

• The effect of CB(1) receptor antagonism in the right basolateral amygdala on conditioned fear and associated analgesia in rats.

  The European journal of neuroscience 20071101

• Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.

  Current atherosclerosis reports 20071101

• The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction.

  JAAPA : official journal of the American Academy of Physician Assistants 20071101

• [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].

  Postepy higieny i medycyny doswiadczalnej (Online) 20071019

• Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.

  The Cochrane database of systematic reviews 20071017

• [Obesity in adults].

  Praxis 20071017

• Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20071001

• Effects of SR141716 and WIN 55,212-2 on tolerance to ethanol in rats using the acute and rapid procedures.

  Psychopharmacology 20071001

• Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling.

  Psychopharmacology 20071001

• The endocannabinoid anandamide inhibits the function of alpha4beta2 nicotinic acetylcholine receptors.

  Molecular pharmacology 20071001

• Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.

  Liver international : official journal of the International Association for the Study of the Liver 20071001

• Drugs in the treatment of obesity: sibutramine, orlistat and rimonabant.

  Public health nutrition 20071001

• Adipose tissue and diabetes therapy: do we hit the target?

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20071001

• [Prevention of cardiovascular disease by blocking the endocannabinoid system].

  Herz 20071001

• Strategies to reduce vascular risk associated with obesity.

  Current vascular pharmacology 20071001

• Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers.

  Current diabetes reports 20071001

• Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity.

  Current diabetes reports 20071001

• The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor.

  European journal of pharmacology 20070910

• Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism.

  Journal of neurochemistry 20070901

• A call to action: new treatment options provide even more reasons to intervene in tobacco dependence.

  Nature clinical practice. Cardiovascular medicine 20070901

• Involvement of CB1 and CB2 receptors in the modulation of cholinergic neurotransmission in mouse gastric preparations.

  Pharmacological research 20070901

• What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?

  The American journal of medicine 20070901

• WIN-55,212-2 chronically implanted into the CA3 region of the dorsal hippocampus impairs learning: a novel method for studying chronic, brain-area-specific effects of cannabinoids.

  Behavioural pharmacology 20070901

• Short-term memory is modulated by the spontaneous release of endocannabinoids: evidence from hippocampal population codes.

  Behavioural pharmacology 20070901

• The safety of obesity drugs.

  Expert opinion on drug safety 20070901

• Role of cannabinoidergic mechanisms in ethanol self-administration and ethanol seeking in rat adult offspring following perinatal exposure to Delta9-tetrahydrocannabinol.

  Toxicology and applied pharmacology 20070815

• Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.

  European journal of pharmacology 20070813

• Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity.

  Journal of the American College of Cardiology 20070807

• Endocannabinoid inhibition: a new cardioprotective strategy against doxorubicin cardiotoxicity.

  Journal of the American College of Cardiology 20070807

• Combination of rimonabant and donepezil prolongs spatial memory duration.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070801

• NOP receptor antagonist, JTC-801, blocks cannabinoid-evoked hypothermia in rats.

  Neuropeptides 20070801

• The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy.

  British journal of pharmacology 20070801

• Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.

  British journal of pharmacology 20070801

• Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon.

  Pharmacological research 20070801

• Fused-core silica column high-performance liquid chromatography/tandem mass spectrometric determination of rimonabant in mouse plasma.

  Analytical chemistry 20070801

• Evidence for the involvement of cannabinoid CB1 receptors in the bimatoprost-induced contractions on the human isolated ciliary muscle.

  Investigative ophthalmology & visual science 20070801

• Methoxy- and fluorine-substituted analogs of O-1302: synthesis and in vitro binding affinity for the CB1 cannabinoid receptor.

  Chemical & pharmaceutical bulletin 20070801

• Blood pressure-lowering drugs not considered as antihypertensives.

  Current hypertension reports 20070801

• Blocking the cannabinoid receptors: drug candidates and therapeutic promises.

  Chemistry & biodiversity 20070801

• The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.

  Molecular neurobiology 20070801

• Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.

  The Cochrane database of systematic reviews 20070718

• Panel advises against rimonabant approval.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070715

• A comparison of the effects of the CB(1) receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour.

  Psychopharmacology 20070701

• Effects of the cannabinoid CB1 receptor antagonist rimonabant on distinct measures of impulsive behavior in rats.

  Psychopharmacology 20070701

• MDMA attenuates THC withdrawal syndrome in mice.

  Psychopharmacology 20070701

• The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses hippocampal firing rate in rats.

  British journal of pharmacology 20070701

• Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats.

  Hepatology (Baltimore, Md.) 20070701

• [New concepts in the treatment of type 2 diabetes].

  Der Internist 20070701

• Smoking cessation: lessons learned from clinical trial evidence.

  Current opinion in cardiology 20070701

• Involvement of the endocannabinoid system in retinal damage after high intraocular pressure-induced ischemia in rats.

  Investigative ophthalmology & visual science 20070701

• Cannabinoids and cardiovascular disease: the outlook for clinical treatments.

  Current vascular pharmacology 20070701

• [Cannabinoid receptor blocker rimonabant. CNS side effects prevent U.S. approval].

  MMW Fortschritte der Medizin 20070628

• Cannabinoids inhibit sodium-dependent, high-affinity excitatory amino acid transport in cultured rat cortical astrocytes.

  Biochemical pharmacology 20070615

• Novel inhibitors of fatty acid amide hydrolase.

  Bioorganic & medicinal chemistry letters 20070615

• Cannabinoid CB1 receptors in the paraventricular nucleus and central control of penile erection: immunocytochemistry, autoradiography and behavioral studies.

  Neuroscience 20070615

• Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity.

  Life sciences 20070613

• Attenuation of allergic contact dermatitis through the endocannabinoid system.

  Science (New York, N.Y.) 20070608

• Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature.

  Brain research 20070604

• The cannabinoid antagonist SR 141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food.

  Neuroscience letters 20070604

• Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.

  Molecular pharmacology 20070601

• Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.

  The Journal of pharmacology and experimental therapeutics 20070601

• Persistent synaptic activity produces long-lasting enhancement of endocannabinoid modulation and alters long-term synaptic plasticity.

  Journal of neurophysiology 20070601

• The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism--or inverse agonism--as potential obesity treatment and other therapeutic use.

  Journal of clinical pharmacy and therapeutics 20070601

• Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes.

  European heart journal 20070601

• Effects of combined oleoyl-estrone and rimonabant on overweight rats.

  Journal of pharmacological sciences 20070601

• Less weight or more hype with rimonabant?

  Drug and therapeutics bulletin 20070601

• The endocannabinoid system: a new target for the regulation of energy balance and metabolism.

  Critical pathways in cardiology 20070601

• Cardiovascular disease under the influence of excess visceral fat.

  Critical pathways in cardiology 20070601

• Rimonabant for treating tobacco dependence.

  Vascular health and risk management 20070601

• [Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes].

  Annales d'endocrinologie 20070601

• Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070501

• The link between abdominal obesity, metabolic syndrome and cardiovascular disease.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20070501

• Depolarization-induced rapid generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in rat brain synaptosomes.

  Journal of biochemistry 20070501

• Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

  British journal of pharmacology 20070501

• The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.

  Journal of clinical pharmacology 20070501

• Cannabinoid and vanilloid effects of R(+)-methanandamide in the hemisected meningeal preparation.

  Cephalalgia : an international journal of headache 20070501

• Rimonabant as potential treatment for the neglected epidemic of diabetes in the Middle East and Arabian Peninsula. Implication for prevention.

  Saudi medical journal 20070501

• Drug treatment of the overweight patient.

  Gastroenterology 20070501

• Interactions between endocannabinoids and stress-induced decreased sensitivity to natural reward.

  Progress in neuro-psychopharmacology & biological psychiatry 20070413

• [New therapeutic aspects for the control of risk factors in obesity].

  Medicina clinica 20070407

• The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific.

  Psychopharmacology 20070401

• Medial forebrain bundle stimulation evokes endocannabinoid-mediated modulation of ventral tegmental area dopamine neuron firing in vivo.

  Psychopharmacology 20070401

• Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients.

  Diabetes & metabolism 20070401

• Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates.

  Pharmacology, biochemistry, and behavior 20070401

• New oral agents for type 2 diabetes.

  Clinical medicine (London, England) 20070401

• Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.

  Vascular health and risk management 20070401

• The endocannabinoid system as a novel approach for managing obesity.

  The Journal of the American Osteopathic Association 20070401

• Modulation of morphine and alcohol motor stimulant effects by cannabinoid receptors ligands.

  Behavioural brain research 20070328

• Delta9-tetrahydrocannabinol (Delta9-THC) prevents cerebral infarction via hypothalamic-independent hypothermia.

  Life sciences 20070327

• Cannabinoid CB1 receptor antagonism markedly increases dopamine receptor-mediated stereotypies.

  European journal of pharmacology 20070322

• 2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling.

  European journal of pharmacology 20070322

• [Internal medicine--update 2006].

  Praxis 20070314

• Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain.

  Neuroscience 20070302

• Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070301

• A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide.

  The Journal of pharmacology and experimental therapeutics 20070301

• Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement.

  Psychopharmacology 20070301

• Rimonabant: more than an anti-obesity drug?

  British journal of pharmacology 20070301

• Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats.

  British journal of pharmacology 20070301

• Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

  British journal of pharmacology 20070301

• Genetic and pharmacological approaches to evaluate the interaction between the cannabinoid and cholinergic systems in cognitive processes.

  British journal of pharmacology 20070301

• Antagonism of type-1 cannabinoid receptors: good for obesity, but is it safe for fertility?

  Clinical endocrinology 20070301

• Repeated treatment with cannabidiol but not Delta9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance.

  Neuropharmacology 20070301

• Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070301

• [Cannabis and cannabinoids as drugs].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20070301

• [Endocannabinoids: therapeutic perspectives in chronic liver diseases].

  Gastroenterologie clinique et biologique 20070301

• Chronic cocaine sensitizes striatal GABAergic synapses to the stimulation of cannabinoid CB1 receptors.

  The European journal of neuroscience 20070301

• Rimonabant in obese patients with type 2 diabetes.

  Lancet (London, England) 20070217

• Rimonabant in obese patients with type 2 diabetes.

  Lancet (London, England) 20070217

• Rimonabant in obese patients with type 2 diabetes.

  Lancet (London, England) 20070217

• Rimonabant in obese patients with type 2 diabetes.

  Lancet (London, England) 20070217

• The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol.

  Neurobiology of disease 20070201

• Cannabimimetic properties of ajulemic acid.

  The Journal of pharmacology and experimental therapeutics 20070201

• Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.

  Bioorganic & medicinal chemistry letters 20070201

• The effects of anorexic drugs on free-fed rats responding under a second-order FI15-min (FR10:S) schedule for high incentive foods.

  Behavioural pharmacology 20070201

• Endocannabinoid antagonism: blocking the excess in the treatment of high-risk abdominal obesity.

  Trends in cardiovascular medicine 20070201

• Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

  The American journal of medicine 20070201

• CB2 cannabinoid receptors promote mouse neural stem cell proliferation.

  The European journal of neuroscience 20070201

• [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes].

  Revue medicale de Liege 20070201

• Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20070124

• Antidepressant-induced undesirable weight gain: prevention with rimonabant without interference with behavioral effectiveness.

  European journal of pharmacology 20070112

• Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

  Lancet (London, England) 20070106

• Cannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsy.

  Neuroscience letters 20070103

• WIN-55,212-2 and SR-141716A alter nicotine-induced changes in locomotor activity, but do not alter nicotine-evoked [3H]dopamine release.

  Life sciences 20070102

• Genetic impairment of frontocortical endocannabinoid degradation and high alcohol preference.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20070101

• An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives.

  Brain research reviews 20070101

• The obesity epidemic: current and future pharmacological treatments.

  Annual review of pharmacology and toxicology 20070101

• Anandamide inhibits endothelin-1 production by human cultured endothelial cells: a new vascular action of this endocannabinoid.

  Pharmacology 20070101

• [Rimonabant actions on cardiometabolic risk factors].

  Medizinische Monatsschrift fur Pharmazeuten 20070101

• Cannabinoid receptor antagonists and the metabolic syndrome: Novel promising therapeutical approaches.

  Mini reviews in medicinal chemistry 20070101

• Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.

  Preventive cardiology 20070101

• Special report on the Sanofi-Aventis cardiometabolic symposium.

  Cardiovascular journal of Africa 20070101

• Novel therapies for cardiometabolic risk reduction and implications for clinical practice.

  Reviews in cardiovascular medicine 20070101

• Reducing cardiometabolic risk through selective antagonism of CB1 receptors.

  Clinical cornerstone 20070101

• Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.

  Cardiovascular journal of Africa 20070101

• [Pharmacology of cannabinoid receptors].

  Bulletin de l'Academie nationale de medecine 20070101

• Overweight and obesity: key components of cardiometabolic risk.

  Clinical cornerstone 20070101

• Evaluation of the role of the arachidonic acid cascade in anandamide's in vivo effects in mice.

  Life sciences 20061203

• Cannabinoid CB1 receptor antagonism modulates plasma corticosterone in rodents.

  European journal of pharmacology 20061203

• Anxiolytic-like properties of the anandamide transport inhibitor AM404.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20061201

• The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids.

  Pflugers Archiv : European journal of physiology 20061201

• Effects of a cannabinoid agonist on spinal nociceptive neurons in a rodent model of neuropathic pain.

  Journal of neurophysiology 20061201

• In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids.

  Journal of neuroimmunology 20061201

• Rimonabant: endocannabinoid inhibition for the metabolic syndrome.

  International journal of clinical practice 20061201

• Metabolic syndrome treatment strategies.

  Pharmacotherapy 20061201

• Emerging strategies for increasing high-density lipoprotein.

  The American journal of cardiology 20061201

• Effects of rimonabant (SR141716) on fasting-induced hypothalamic-pituitary-adrenal axis and neuronal activation in lean and obese Zucker rats.

  Diabetes 20061201

• [Pharmacotherapy of obesity].

  Medizinische Monatsschrift fur Pharmazeuten 20061201

• Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs.

  The AAPS journal 20061201

• Cardiometabolic risk modification: current trends and emerging therapies.

  JAAPA : official journal of the American Academy of Physician Assistants 20061201

• The cannabinoid receptor agonist, WIN 55,212-2, inhibits cool-specific lamina I medullary dorsal horn neurons.

  Neuroscience 20061117

• [A drug for therapy of obesity: really only life style? (interview by Dirk Einecke)].

  MMW Fortschritte der Medizin 20061116

• Does rimonabant pull its weight for type 2 diabetes?

  Lancet (London, England) 20061111

• Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

  Lancet (London, England) 20061111

• Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 and carbon monoxide reduces extracellular glutamate levels in primary rat cerebral cortex cell cultures.

  Neurochemistry international 20061101

• Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats.

  Psychopharmacology 20061101

• Rimonabant as a potential new treatment for an emerging epidemic of obesity-related glomerulopathy?

  Expert opinion on emerging drugs 20061101

• [Acomplia, an essential medication or a 'comfort' product?].

  Revue medicale suisse 20061101

• The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome.

  Annals of the New York Academy of Sciences 20061101

• Role of cannabinoid receptors in the regulation of cardiac contractility during ischemia/reperfusion.

  Bulletin of experimental biology and medicine 20061101

• Rimonabant for overweight or obesity.

  The Cochrane database of systematic reviews 20061018

• Cannabinoid receptor-mediated inhibition of calcium signaling in rat retinal ganglion cells.

  Molecular vision 20061006

• Better strategies sought against obesity.

  JAMA 20061004

• Protective activation of the endocannabinoid system during ischemia in dopamine neurons.

  Neurobiology of disease 20061001

• The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism.

  Molecular pharmacology 20061001

• CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action.

  Molecular pharmacology 20061001

• Discriminative stimulus functions of AM-1346, a CB1R selective anandamide analog in rats trained with Delta9-THC or (R)-methanandamide (AM-356).

  Psychopharmacology 20061001

• Effects of endocannabinoid neurotransmission modulators on brain stimulation reward.

  Psychopharmacology 20061001

• Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.

  Psychopharmacology 20061001

• Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20061001

• 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors.

  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20061001

• Obesity drug development - CBI's 2nd Annual Summit.

  IDrugs : the investigational drugs journal 20061001

• Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system.

  The European journal of neuroscience 20061001

• Pharmacotherapy of obesity.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20061001

• Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.

  European journal of pharmacology 20060928

• Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice.

  The Journal of physiology 20060915

• A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation.

  Brain research 20060907

• Effects of the cannabinoid CB1 receptor agonist CP55,940 and antagonist SR141716A on d-amphetamine-induced behaviours in Cebus monkeys.

  Journal of psychopharmacology (Oxford, England) 20060901

• Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic.

  Neuropharmacology 20060901

• Interactions between CB1 cannabinoid and mu opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core.

  Neuropharmacology 20060901

• Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra.

  Acta neuropathologica 20060901

• SR 141716 (Rimonabant) precipitates withdrawal in marijuana-dependent mice.

  Pharmacology, biochemistry, and behavior 20060901

• Effects of the CB1R agonist WIN-55,212-2 and the CB1R antagonists SR-141716 and AM-1387: open-field examination in rats.

  Pharmacology, biochemistry, and behavior 20060901

• [Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke].

  MMW Fortschritte der Medizin 20060831

• Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.

  Circulation 20060829

• Endogenous cannabinoid signaling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060823

• [Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies].

  Revue medicale suisse 20060823

• Morphine reduces penile erection induced by the cannabinoid receptor antagonist SR 141617A in male rats: role of paraventricular glutamic acid and nitric oxide.

  Neuroscience letters 20060814

• Effect of rimonabant on weight and cardiometabolic risk factors.

  JAMA 20060809

• Early tolerance to the hypophagic effect of the cannabinoid receptor antagonist SR141716 does not impede blockade of an orexigenic stimulus.

  European journal of pharmacology 20060807

• Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233.

  Synapse (New York, N.Y.) 20060801

• Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole--LH 21.

  Neuropharmacology 20060801

• Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips.

  British journal of pharmacology 20060801

• Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats.

  Pediatric research 20060801

• Coming soon: the lose-weight-stop-smoking pill that's good for your heart.

  Health news (Waltham, Mass.) 20060801

• Pharmacologic treatment for obesity. Options for today...and tomorrow.

  Advance for nurse practitioners 20060801

• [Rimonabant--a panacea for patients with metabolic syndrome?].

  Polskie Archiwum Medycyny Wewnetrznej 20060801

• [Blockage of the CB1 cannabinoid receptor for the prevention of liver cirrhosis ].

  Revue medicale suisse 20060712

• Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P.

  Gut 20060701

• Synthesis and preliminary biological evaluation of [123I]Me2Pyr, a new potential ligand for imaging of central cannabinoid CB1 receptors.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20060701

• Sphingosine and its analog, the immunosuppressant 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol, interact with the CB1 cannabinoid receptor.

  Molecular pharmacology 20060701

• The obesity epidemic and its cardiovascular consequences.

  Current opinion in cardiology 20060701

• Amygdala BDNF signaling is required for consolidation but not encoding of extinction.

  Nature neuroscience 20060701

• SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats.

  Alcohol (Fayetteville, N.Y.) 20060701

• CB1 knockout mice display significant changes in striatal opioid peptide and D4 dopamine receptor gene expression.

  Brain research 20060606

• CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.

  Nature medicine 20060601

• The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.

  Pharmacology, biochemistry, and behavior 20060601

• Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice.

  Pharmacology, biochemistry, and behavior 20060601

• [Impact of endocannabinoid system in modulation of cardiometabolic risk factors].

  Vnitrni lekarstvi 20060601

• Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors.

  Journal of the American College of Cardiology 20060516

• The cannabinoid CB1 receptor antagonist SR 141716A induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats.

  Behavioural brain research 20060515

• Treatments for metabolic syndrome may expand.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20060515

• Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization.

  Biochemistry 20060502

• Cannabinoid effects on behaviors maintained by ethanol or food: a within-subjects comparison.

  Behavioural pharmacology 20060501

• Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule cells via activation of the CB1 receptor and downregulation of bcl-xL gene expression.

  Journal of neuroscience research 20060501

• Update on rimonabant--a selective cannabinoid CB1 antagonist.

  The Annals of pharmacotherapy 20060501

• Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility.

  Investigative ophthalmology & visual science 20060501

• Cannabinoid modulation of electrically evoked pH and oxygen transients in the nucleus accumbens of awake rats.

  Journal of neurochemistry 20060501

• Cannabinoids modulate spontaneous neuronal activity and evoked inhibition of locus coeruleus noradrenergic neurons.

  The European journal of neuroscience 20060501

• Role of the basolateral nucleus of the amygdala in endocannabinoid-mediated stress-induced analgesia.

  Neuroscience letters 20060424

• Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060401

• Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats.

  Psychopharmacology 20060401

• Diabetes: assessing the pipeline.

  Atherosclerosis. Supplements 20060401

• Optimal treatments for the metabolic syndrome.

  Arteriosclerosis, thrombosis, and vascular biology 20060401

• The unfolding cannabinoid story on energy homeostasis: central or peripheral site of action?

  International journal of obesity (2005) 20060401

• Contribution of CB1 blockade to the management of high-risk abdominal obesity.

  International journal of obesity (2005) 20060401

• Role of TRPV1 and cannabinoid CB1 receptors in AM 404-evoked hypothermia in rats.

  Pharmacology, biochemistry, and behavior 20060401

• Pharmacological treatment of obesity.

  Arquivos brasileiros de endocrinologia e metabologia 20060401

• The new cancer fighter (and other hot drugs on the way).

  Time 20060320

• Systemic effect of cannabinoids on the spontaneous firing rate of locus coeruleus neurons in rats.

  European journal of pharmacology 20060318

• The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20060315

• Metabolic risk factors, drugs, and obesity.

  The New England journal of medicine 20060302

• [Pharmacotherapy in the treatment of obesity].

  MMW Fortschritte der Medizin 20060302

• Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity.

  Molecular pharmacology 20060301

• Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia.

  Neuropharmacology 20060301

• Role of the cannabinoid system in the effects induced by nicotine on anxiety-like behaviour in mice.

  Psychopharmacology 20060301

• Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection.

  British journal of pharmacology 20060301

• Effects of castration on cannabinoid cb receptor expression and on the biological actions of cannabinoid in the parotid gland.

  Clinical and experimental pharmacology & physiology 20060301

• Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20060301

• Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors.

  Expert opinion on investigational drugs 20060301

• The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers.

  American heart journal 20060301

• Pharmacologic interventions for smoking cessation.

  Critical care nursing clinics of North America 20060301

• Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.

  Brain research 20060216

• Anandamide inhibits adhesion and migration of breast cancer cells.

  Experimental cell research 20060215

• The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors.

  European journal of pharmacology 20060215

• Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.

  JAMA 20060215

• Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.

  Journal of medicinal chemistry 20060209

• New bicyclic cannabinoid receptor-1 (CB1-R) antagonists.

  Bioorganic & medicinal chemistry letters 20060201

• The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.

  Molecular pharmacology 20060201

• The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: involvement of paraventricular glutamic acid and nitric oxide.

  Neuropharmacology 20060201

• Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data.

  Digestive diseases and sciences 20060201

• Drug development. Drugs inspired by a drug.

  Science (New York, N.Y.) 20060120

• Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'.

  European journal of pharmacology 20060113

• [Drug treatment of obesity].

  Ugeskrift for laeger 20060109

• The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats.

  Behavioural brain research 20060106

• [New obesity and metabolic syndrome treatment: rimonabant].

  Revue medicale suisse 20060104

• Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice.

  Neurobiology of disease 20060101

• Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions.

  Journal of psychopharmacology (Oxford, England) 20060101

• Pharmacological manipulation of CB1 receptor function alters development of tolerance to alcohol.

  Alcohol and alcoholism (Oxford, Oxfordshire) 20060101

• Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats.

  Psychopharmacology 20060101

• Structural-activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides.

  European journal of medicinal chemistry 20060101

• Antagonism of discriminative stimulus effects of delta(9)-THC and (R)-methanandamide in rats.

  Psychopharmacology 20060101

• The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats.

  Psychopharmacology 20060101

• American Heart Association--scientific sessions 2005. Potential new drugs for various indications. 13-16 November 2005, Dallas, TX, USA.

  IDrugs : the investigational drugs journal 20060101

• Rimonabant adds appetizing choice to slim obesity market.

  Nature medicine 20060101

• Pharmacologic treatment of obesity.

  Advances in psychosomatic medicine 20060101

• Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain.

  Pharmacology 20060101

• [Reducing obesity].

  Presse medicale (Paris, France : 1983) 20060101

• Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions.

  Methods in molecular medicine 20060101

• Contemporary strategies for managing cardiometabolic risk factors.

  Journal of managed care pharmacy : JMCP 20060101

• Clinical outcomes in metabolic syndrome.

  The Journal of cardiovascular nursing 20060101

• The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.

  The American journal of geriatric cardiology 20060101

• Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk.

  Asia Pacific journal of clinical nutrition 20060101

• Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.

  CNS drug reviews 20060101

• Therapeutic potential of targeting the endocannabinoids: implications for the treatment of obesity, metabolic syndrome, drug abuse and smoking cessation.

  Current medicinal chemistry 20060101

• Rimonabant.

  Drugs 20060101

• [Selective cannabinoid receptor antagonists].

  Pharmazie in unserer Zeit 20060101

• Involvement of cannabinoid CB1 receptors in drug addiction: effects of rimonabant on behavioral responses induced by cocaine.

  Pharmacological reports : PR 20060101

• In vitro effects of CB1 receptor ligands on lipid peroxidation and antioxidant defense systems in the rat brain.

  Pharmacological reports : PR 20060101

• In vivo effects of CB1 receptor ligands on lipid peroxidation and antioxidant defense systems in the rat brain of healthy and ethanol-treated rats.

  Pharmacological reports : PR 20060101

• Endocannabinoids--the brain's own marijuana--may be linked to the metabolic syndrome.

  MedGenMed : Medscape general medicine 20060101

• The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.

  Proceedings of the National Academy of Sciences of the United States of America 20051227

• Decrease in prostaglandin level is a prerequisite for the expression of cannabinoid withdrawal: a quasi abstinence approach.

  Brain research 20051220

• Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.

  FEBS letters 20051219

• Dual Ca2+ modulation of glycinergic synaptic currents in rodent hypoglossal motoneurones.

  The Journal of physiology 20051215

• Capsaicin evokes hypothermia independent of cannabinoid CB1 and CB2 receptors.

  Brain research 20051214

• Paraventricular hypothalamic CB(1) cannabinoid receptors are involved in the feeding stimulatory effects of Delta(9)-tetrahydrocannabinol.

  Neuropharmacology 20051201

• Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla.

  Neuropharmacology 20051201

• Involvement of the endogenous cannabinoid system in the effects of alcohol in the mesolimbic reward circuit: electrophysiological evidence in vivo.

  Psychopharmacology 20051201

• Tackling obesity and nicotine dependence.

  IDrugs : the investigational drugs journal 20051201

• Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction.

  Current drug targets. Cardiovascular & haematological disorders 20051201

• [The formidable virtue announced for rimonabant, alias Acomplia].

  Revue medicale suisse 20051130

• Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

  The New England journal of medicine 20051117

• Pharmacotherapy for obesity--promise and uncertainty.

  The New England journal of medicine 20051117

• Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20051101

• Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures.

  Glia 20051101

• Allosteric modulation of the cannabinoid CB1 receptor.

  Molecular pharmacology 20051101

• Safety of obesity drugs.

  Expert opinion on drug safety 20051101

• Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus.

  The European journal of neuroscience 20051101

• [Medications in smoking cessation].

  Presse medicale (Paris, France : 1983) 20051022

• Anandamide elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation in the rat arterial mesenteric bed.

  The Journal of physiology 20051015

• Weeding out new drugs.

  Drug discovery today 20051015

• Involvement of the cannabinoid CB1 receptor in the opioid inhibition of the response to cholecystokinin and acute withdrawal response.

  Neurotoxicology 20051001

• Inhibition of cyclooxygenase-2 elicits a CB1-mediated decrease of excitatory transmission in rat CA1 hippocampus.

  Neuropharmacology 20051001

• Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats.

  Psychopharmacology 20051001

• VR1-mediated depressor effects during high-salt intake: role of anandamide.

  Hypertension (Dallas, Tex. : 1979) 20051001

• Endocannabinoids and liver disease--review.

  Liver international : official journal of the International Association for the Study of the Liver 20051001

• Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?

  Expert opinion on pharmacotherapy 20051001

• New drugs for prevention, relief. How you might benefit if 3 medications win FDA approval.

  Heart advisor 20051001

• A new 'wonder drug'?

  Diabetes forecast 20051001

• Appetite downer awaits approval.

  Nature 20050929

• Rimonabant: the first therapeutically relevant cannabinoid antagonist.

  Life sciences 20050923

• Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities.

  Bioorganic & medicinal chemistry 20050915

• Retrograde endocannabinoid regulation of GABAergic inhibition in the rat dentate gyrus granule cell.

  The Journal of physiology 20050915

• FDA standards--good enough for government work?

  The New England journal of medicine 20050908

• Lack of CB1 cannabinoid receptor impairs cocaine self-administration.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20050901

• The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050901

• Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways.

  International archives of allergy and immunology 20050901

• New options for drug treatment of obesity in patients with Type 2 diabetes.

  Diabetic medicine : a journal of the British Diabetic Association 20050901

• Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders.

  Behavioural pharmacology 20050901

• SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys.

  Behavioural pharmacology 20050901

• Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.

  Behavioural pharmacology 20050901

• The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940).

  Behavioural pharmacology 20050901

• Long-term behavioural and neuroendocrine effects of perinatal activation or blockade of CB1 cannabinoid receptors.

  Behavioural pharmacology 20050901

• Behaviorally relevant endocannabinoid action in hippocampus: dependence on temporal summation of multiple inputs.

  Behavioural pharmacology 20050901

• [In diabetes cannabinoid antagonist kills two birds with one stone].

  MMW Fortschritte der Medizin 20050901

• [Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)].

  Revue medicale de Bruxelles 20050901

• Cannabinoid CB1 receptors control conditioned drug seeking.

  Trends in pharmacological sciences 20050801

• A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena.

  Experimental neurology 20050801

• [Rimonabant reduced body weight and blood sugar].

  Medizinische Monatsschrift fur Pharmazeuten 20050801

• Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta.

  Naunyn-Schmiedeberg's archives of pharmacology 20050801

• Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.

  Drugs of today (Barcelona, Spain : 1998) 20050801

• WIN 55,212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT(3) receptor function.

  European journal of pharmacology 20050704

• Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.

  The Journal of pharmacology and experimental therapeutics 20050701

• A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20050701

• Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve.

  Pain 20050701

• Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats.

  The European journal of neuroscience 20050701

• Effect of rimonabant on weight reduction and cardiovascular risk.

  Lancet (London, England) 20050701

• Effect of rimonabant on weight reduction and cardiovascular risk.

  Lancet (London, England) 20050701

• Effect of rimonabant on weight reduction and cardiovascular risk.

  Lancet (London, England) 20050701

• Effect of rimonabant on weight reduction and cardiovascular risk.

  Lancet (London, England) 20050701

• [Medication for ending tobacco dependency. Current state].

  Atencion primaria 20050630

• Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an immunohistochemical study.

  Brain research 20050628

• Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding.

  Biochemistry 20050621

• Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.

  Biological psychiatry 20050615

• The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050608

• The cannabinoid antagonist SR141716A facilitates memory acquisition and consolidation in the mouse elevated T-maze.

  Neuroscience letters 20050603

• Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A.

  Behavioural brain research 20050603

• Disruption of CB(1) receptor signaling impairs extinction of spatial memory in mice.

  Psychopharmacology 20050601

• CB1 cannabinoid receptor-mediated modulation of food intake in mice.

  British journal of pharmacology 20050601

• The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide.

  British journal of pharmacology 20050601

• Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction.

  Neuropharmacology 20050601

• Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores.

  Neuropharmacology 20050601

• Cannabinoid CB(1) antagonist SR 141716A attenuates reinstatement of heroin self-administration in heroin-abstinent rats.

  Neuropharmacology 20050601

• Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.

  Neuropharmacology 20050601

• Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens.

  Neuropharmacology 20050601

• Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat.

  European journal of pharmacology 20050509

• [Highlights from the American College of Cardiology Annual Scientific Session 2005: March 5-9, 2005, Orlando, Florida].

  Revue medicale suisse 20050504

• Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors.

  Bioorganic & medicinal chemistry 20050502

• The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food.

  Psychopharmacology 20050501

• CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat.

  Psychopharmacology 20050501

• Endocannabinoid control of food intake and energy balance.

  Nature neuroscience 20050501

• Evidence for novel cannabinoid receptors.

  Pharmacology & therapeutics 20050501

• Cannabinoid receptor antagonists SR141716 and SR144528 exhibit properties of partial agonists in experiments on isolated perfused rat heart.

  Bulletin of experimental biology and medicine 20050501

• Protective effects of Delta(9)-tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death.

  Brain research. Molecular brain research 20050404

• In vitro metabolism of diarylpyrazoles, a novel group of cannabinoid receptor ligands.

  Drug metabolism and disposition: the biological fate of chemicals 20050401

• Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury.

  The Journal of pharmacology and experimental therapeutics 20050401

• Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism.

  Neurobiology of disease 20050401

• Rimonabant--a selective CB1 antagonist.

  The Annals of pharmacotherapy 20050401

• [Innovation instead of imitation -- news in drug therapy].

  Deutsche medizinische Wochenschrift (1946) 20050401

• Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors.

  Lancet (London, England) 20050401

• Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.

  Lancet (London, England) 20050401

• Obesity and cardiovascular physiology: impact of some pharmacological agents.

  Current vascular pharmacology 20050401

• Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats.

  The European journal of neuroscience 20050401

• Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists.

  Journal of medicinal chemistry 20050324

• [Blocking the endocannabinoid system -- weight reduction and cardiovascular risk management].

  Deutsche medizinische Wochenschrift (1946) 20050324

• Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20050316

• Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice.

  Brain research bulletin 20050315

• Cannabinoid receptor as a novel target for the treatment of prostate cancer.

  Cancer research 20050301

• Will the new CB1 cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?

  Expert opinion on investigational drugs 20050301

• Inverse agonism and neutral antagonism at cannabinoid CB1 receptors.

  Life sciences 20050204

• Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice.

  International journal of obesity (2005) 20050201

• Human sperm express cannabinoid receptor Cb1, the activation of which inhibits motility, acrosome reaction, and mitochondrial function.

  The Journal of clinical endocrinology and metabolism 20050201

• 3,4 Methylenedioxymethamphetamine-induced conditioned place preference (CPP) is mediated by endocannabinoid system.

  Pharmacological research 20050201

• The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro.

  Journal of neuroimmunology 20050201

• Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents.

  Biological psychiatry 20050201

• [Endocannabinoid and endocannabinoid receptor antagonists].

  Medizinische Monatsschrift fur Pharmazeuten 20050201

• Another pill for weight reduction.

  Clinical cardiology 20050201

• Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling.

  The European journal of neuroscience 20050201

• New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?

  Heart advisor 20050201

• Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes.

  Glia 20050115

• [Nutrition--obesity].

  Revue medicale suisse 20050105

• Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20050101

• Role of the endocannabinoid system in the development of tolerance to alcohol.

  Alcohol and alcoholism (Oxford, Oxfordshire) 20050101

• Interactions between cannabinoid and opioid receptor systems in the mediation of ethanol effects.

  Alcohol and alcoholism (Oxford, Oxfordshire) 20050101

• Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility.

  Molecular human reproduction 20050101

• Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization.

  European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20050101

• Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats.

  Alcohol and alcoholism (Oxford, Oxfordshire) 20050101

• The anti-obesity effect of rimonabant is associated with an improved serum lipid profile.

  Diabetes, obesity & metabolism 20050101

• Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system.

  Naunyn-Schmiedeberg's archives of pharmacology 20050101

• Cannabis antagonists: a new era of social psychopharmacology?

  Journal of psychopharmacology (Oxford, England) 20050101

• [Endocannabinoids--the new option in the treatment of metabolic syndrome and in smoking cessation].

  Casopis lekaru ceskych 20050101

• Cannabinoids depress excitatory neurotransmission between the subthalamic nucleus and the globus pallidus.

  Neuroscience 20050101

• Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat.

  Neuroscience 20050101

• Rimonabant: unique and promising.

  Preventive cardiology 20050101

• [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].

  Revue medicale de Bruxelles 20050101

• Cocaine- and amphetamine-related transcript is involved in the orexigenic effect of endogenous anandamide.

  Neuroendocrinology 20050101

• [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].

  Journal de pharmacie de Belgique 20050101

• The endocannabinoid system: a new approach to control cardiovascular disease.

  Clinical cornerstone 20050101

• The metabolic basis of atherogenic dyslipidemia.

  Clinical cornerstone 20050101

• Managing cardiovascular risk inpatients with metabolic syndrome.

  Clinical cornerstone 20050101

• Pharmacotherapy to reduce visceral fat.

  Clinical cornerstone 20050101

• Cannabinoid tolerance and dependence.

  Handbook of experimental pharmacology 20050101

• Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors.

  Brain research. Molecular brain research 20041206

• Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats.

  European journal of pharmacology 20041203

• Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist.

  Psychopharmacology 20041201

• Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation.

  Journal of neurophysiology 20041201

• Modulation of morphine-induced Fos-immunoreactivity by the cannabinoid receptor antagonist SR 141716.

  Neuropharmacology 20041201

• The weight debate, continued.

  Managed care (Langhorne, Pa.) 20041201

• (S)-AMPA inhibits electrically evoked calcitonin gene-related peptide (CGRP) release from the rat dorsal horn: reversal by cannabinoid receptor antagonist SR141716A.

  Neuroscience letters 20041130

• A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine.

  Brain research 20041112

• [Endocannabinoids receptor blocker lets tumble not only money. A drug against metabolic syndrome?].

  MMW Fortschritte der Medizin 20041104

• Endocannabinoids link feeding state and auditory perception-related gene expression.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20041103

• Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways.

  American journal of respiratory and critical care medicine 20041101

• The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin.

  British journal of pharmacology 20041101

• (-)-Adamantyl-delta8-tetrahydrocannabinol (AM-411), a selective cannabinoid CB1 receptor agonist: effects on open-field behaviors and antagonism by SR-141716 in rats.

  Behavioural pharmacology 20041101

• Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain.

  The European journal of neuroscience 20041101

• Potential modulation of plasma ghrelin and glucagon-like peptide-1 by anorexigenic cannabinoid compounds, SR141716A (rimonabant) and oleoylethanolamide.

  The British journal of nutrition 20041101

• Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism.

  Neuroreport 20041025

• Cannabinoid inhibition improves memory in food-storing birds, but with a cost.

  Proceedings. Biological sciences 20041007

• Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats.

  European journal of pharmacology 20041006

• Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.

  Circulation 20041005

• Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed.

  The Journal of pharmacology and experimental therapeutics 20041001

• The THC-induced suppression of Th1 polarization in response to Legionella pneumophila infection is not mediated by increases in corticosterone and PGE2.

  Journal of leukocyte biology 20041001

• A new strategy to block tumor growth by inhibiting endocannabinoid inactivation.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20041001

• CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat.

  British journal of pharmacology 20041001

• Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine.

  The European journal of neuroscience 20041001

• Clinical pharmacotherapy for obesity: current drugs and those in advanced development.

  Current drug targets 20041001

• Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences.

  Neuroreport 20040915

• Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats.

  European journal of pharmacology 20040913

• Analysis of the effects of cannabinoids on synaptic transmission between basket and Purkinje cells in the cerebellar cortex of the rat.

  The Journal of pharmacology and experimental therapeutics 20040901

• Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats.

  Psychopharmacology 20040901

• Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.

  British journal of pharmacology 20040901

• Rats on the grog: novel pharmacotherapies for alcohol craving.

  Addictive behaviors 20040901

• Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake.

  Neuropharmacology 20040901

• Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

  American journal of physiology. Heart and circulatory physiology 20040801

• Endocannabinoid system modulates relapse to methamphetamine seeking: possible mediation by the arachidonic acid cascade.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20040801

• Evidence for differential modulation of conditioned aversion and fear-conditioned analgesia by CB1 receptors.

  The European journal of neuroscience 20040801

• Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice.

  British journal of pharmacology 20040801

• A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats.

  Experimental and clinical psychopharmacology 20040801

• Genetic deletion and pharmacological blockade of CB1 receptors modulates anxiety in the shock-probe burying test.

  The European journal of neuroscience 20040801

• Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons.

  Biological psychiatry 20040715

• A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew).

  Psychopharmacology 20040701

• Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake.

  Endocrinology 20040701

• Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model.

  Neurobiology of disease 20040701

• Central effects of the cannabinoid receptor agonist WIN55212-2 on respiratory and cardiovascular regulation in anaesthetised rats.

  British journal of pharmacology 20040701

• TRPV1 and CB(1) receptor-mediated effects of the endovanilloid/endocannabinoid N-arachidonoyl-dopamine on primary afferent fibre and spinal cord neuronal responses in the rat.

  The European journal of neuroscience 20040701

• Inhibitory effect of the antidepressant St. John's wort (hypericum perforatum) on rat bladder contractility in vitro.

  Urology 20040701

• CB1 cannabinoid receptors mediate anxiolytic effects: convergent genetic and pharmacological evidence with CB1-specific agents.

  Behavioural pharmacology 20040701

• Recent advances in CB1 cannabinoid receptor antagonists.

  Current opinion in drug discovery & development 20040701

• Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake.

  Biochemistry 20040629

• Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (Rimonabant).

  European journal of pharmacology 20040628

• The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat.

  European journal of pharmacology 20040616

• Sex-linked differences in the vasorelaxant effects of anandamide in vascular mesenteric beds: role of oestrogens.

  European journal of pharmacology 20040616

• Cannabinoid agonist-induced sensitisation to morphine place preference in mice.

  Neuroreport 20040607

• Cannabinoids enhance N-methyl-D-aspartate-induced excitation of locus coeruleus neurons by CB1 receptors in rat brain slices.

  Neuroscience letters 20040603

• Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA ('Ecstasy') in rats.

  Neuropharmacology 20040601

• Presynaptic cannabinoid CB(1) receptors are involved in the inhibition of the neurogenic vasopressor response during septic shock in pithed rats.

  British journal of pharmacology 20040601

• Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.

  The American journal of psychiatry 20040601

• Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure.

  European journal of heart failure 20040601

• Multiple sclerosis following treatment with a cannabinoid receptor-1 antagonist.

  Multiple sclerosis (Houndmills, Basingstoke, England) 20040601

• Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif.

  Journal of medicinal chemistry 20040520

• Memory reconsolidation and extinction have distinct temporal and biochemical signatures.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040519

• Behavioral and molecular changes elicited by acute administration of SR141716 to Delta9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence.

  Drug and alcohol dependence 20040510

• Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040505

• Blockade by the cannabinoid CB1 receptor antagonist, rimonabant (SR141716), of the potentiation by quinelorane of food-primed reinstatement of food-seeking behavior.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20040501

• Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells.

  Journal of leukocyte biology 20040501

• Retrograde activation of presynaptic NMDA receptors enhances GABA release at cerebellar interneuron-Purkinje cell synapses.

  Nature neuroscience 20040501

• The endogenous cannabinoid system protects against colonic inflammation.

  The Journal of clinical investigation 20040415

• Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erection.

  Neuroscience letters 20040408

• Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats.

  Psychopharmacology 20040401

• Differential effects of delta9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice.

  The Journal of pharmacology and experimental therapeutics 20040401

• CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20040401

• Multiple actions of anandamide on neonatal rat cultured sensory neurones.

  British journal of pharmacology 20040401

• Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity.

  The European journal of neuroscience 20040401

• Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss.

  Pharmacology, biochemistry, and behavior 20040401

• The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice.

  Pharmacology, biochemistry, and behavior 20040401

• Rimonabant Sanofi-Synthélabo.

  Current opinion in investigational drugs (London, England : 2000) 20040401

• [A new pill for metabolic syndrome. Successful control of lipids, kilos and cigarettes].

  MMW Fortschritte der Medizin 20040325

• Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.

  European journal of pharmacology 20040319

• Potent imidazole and triazole CB1 receptor antagonists related to SR141716.

  Bioorganic & medicinal chemistry letters 20040308

• [Blocking cannabinoid receptors. Simultaneous control of overweight and nicotine addiction].

  MMW Fortschritte der Medizin 20040304

• Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia.

  Progress in neuro-psychopharmacology & biological psychiatry 20040301

• Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia?

  Journal of neurochemistry 20040301

• Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid.

  Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 20040301

• Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20040218

• Cannabinoids modulate ultrasound-induced aversive responses in rats.

  Psychopharmacology 20040201

• Cannabinoid receptors and T helper cells.

  Journal of neuroimmunology 20040201

• CB(1) receptor mediation of cannabinoid behavioral effects in male and female rats.

  Psychopharmacology 20040201

• Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.

  Behavioural pharmacology 20040201

• Differential effects of the sleep-inducing lipid oleamide and cannabinoids on the induction of long-term potentiation in the CA1 neurons of the rat hippocampus in vitro.

  Brain research 20040130

• Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats.

  Neuroscience letters 20040116

• Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon.

  American journal of physiology. Gastrointestinal and liver physiology 20040101

• Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20040101

• Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew).

  Psychopharmacology 20040101

• Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A.

  European journal of pharmacology 20040101

• Cannabinoids and the human uterus during pregnancy.

  American journal of obstetrics and gynecology 20040101

• Long-term effects on cortical glutamate release induced by prenatal exposure to the cannabinoid receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone: an in vivo microdialysis study in the awake rat.

  Neuroscience 20040101

• Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease.

  Clinical neuropharmacology 20040101

• Molecule of the month. Rimonabant hydrochloride.

  Drug news & perspectives 20040101

• Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals.

  Alcohol and alcoholism (Oxford, Oxfordshire) 20040101

• Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia.

  Neuroscience 20040101

• Enhancement of androgen receptor expression induced by (R)-methanandamide in prostate LNCaP cells.

  FEBS letters 20031218

• Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20031203

• An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptors.

  British journal of pharmacology 20031201

• A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia.

  Anesthesiology 20031201

• SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats.

  The European journal of neuroscience 20031201

• The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats.

  Behavioural pharmacology 20031201

• An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region.

  Journal of medicinal chemistry 20031120

• Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A.

  Pharmacology 20031101

• Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in delta -sup-9-tetrahydrocannabinol-treated rhesus monkeys.

  Experimental and clinical psychopharmacology 20031101

• Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20031015

• CB1 cannabinoid receptors and on-demand defense against excitotoxicity.

  Science (New York, N.Y.) 20031003

• Effects of direct periaqueductal grey administration of a cannabinoid receptor agonist on nociceptive and aversive responses in rats.

  Neuropharmacology 20031001

• Hypotensive effect of anandamide through the activation of CB1 and VR1 spinal receptors in urethane-anesthetized rats.

  Naunyn-Schmiedeberg's archives of pharmacology 20031001

• Activation of peripheral cannabinoid CB1 receptors inhibits mechanically evoked responses of spinal neurons in noninflamed rats and rats with hindpaw inflammation.

  The European journal of neuroscience 20031001

• Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action.

  The European journal of neuroscience 20031001

• Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.

  Journal of endocrinological investigation 20031001

• Potentiation of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats.

  Neuroscience letters 20030925

• SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task.

  European journal of pharmacology 20030923

• Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade.

  European journal of pharmacology 20030923

• Inhibitory effect of anandamide on resiniferatoxin-induced sensory neuropeptide release in vivo and neuropathic hyperalgesia in the rat.

  Life sciences 20030919

• Cannabinoid modulation of sensitivity to time.

  Behavioural brain research 20030915

• Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction.

  Cellular signalling 20030901

• Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents.

  British journal of pharmacology 20030901

• Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release.

  British journal of pharmacology 20030901

• Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation.

  British journal of pharmacology 20030901

• Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.

  The European journal of neuroscience 20030901

• Functional localization of cannabinoid receptors and endogenous cannabinoid production in distinct neuron populations of the hippocampus.

  The European journal of neuroscience 20030801

• Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030723

• The effect of cannabinoid receptor antagonism with SR141716A on antinociception induced by cocaine and the NMDA receptor antagonist, MK-801.

  Brain research bulletin 20030715

• The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats.

  The Journal of pharmacology and experimental therapeutics 20030701

• The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine.

  Psychopharmacology 20030701

• Anxiety does not affect the antinociceptive effect of Delta 9-THC in mice: participation of cannabinoid and opioid receptors.

  Pharmacology, biochemistry, and behavior 20030701

• Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover.

  Pharmacology, biochemistry, and behavior 20030701

• The cannabinoid receptor antagonist SR-141716 does not readily antagonize open-field effects induced by the cannabinoid receptor agonist (R)-methanandamide in rats.

  Pharmacology, biochemistry, and behavior 20030701

• Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.

  The Journal of biological chemistry 20030627

• Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030615

• Overeating, alcohol and sucrose consumption decrease in CB1 receptor deleted mice.

  Neuroscience letters 20030612

• Neuroprotection by the cannabinoid agonist WIN-55212 in an in vivo newborn rat model of acute severe asphyxia.

  Brain research. Molecular brain research 20030610

• Subversion and utilization of the host cell cyclic adenosine 5'-monophosphate/protein kinase A pathway by Brucella during macrophage infection.

  Journal of immunology (Baltimore, Md. : 1950) 20030601

• Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.

  British journal of pharmacology 20030601

• Endocannabinoids protect the rat isolated heart against ischaemia.

  British journal of pharmacology 20030601

• Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro.

  The European journal of neuroscience 20030601

• WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation.

  Behavioural brain research 20030515

• Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A.

  Biochemical pharmacology 20030515

• Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.

  Neuroreport 20030506

• Microinjection of a cannabinoid receptor antagonist into the NTS increases baroreflex duration in dogs.

  American journal of physiology. Heart and circulatory physiology 20030501

• The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression.

  Naunyn-Schmiedeberg's archives of pharmacology 20030501

• Cannabinoid receptor activation differentially modulates ion channels in photoreceptors of the tiger salamander.

  Journal of neurophysiology 20030501

• A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.

  Pain 20030501

• (R)-Methanandamide and delta9-tetrahydrocannabinol-induced operant rate decreases in rats are not readily antagonized by SR-141716A.

  European journal of pharmacology 20030411

• Experimental drugs take aim at obesity.

  JAMA 20030409

• Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats.

  Psychopharmacology 20030401

• The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.

  Molecular pharmacology 20030401

• Differential cannabinoid-induced electrophysiological effects in rat ventral tegmentum.

  Neuropharmacology 20030401

• Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery.

  British journal of pharmacology 20030401

• Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats.

  European journal of pharmacology 20030328

• Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells.

  European journal of pharmacology 20030319

• Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.

  Brain research 20030314

• Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line.

  International journal of cancer 20030310

• Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart.

  Life sciences 20030307

• Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea.

  Psychopharmacology 20030301

• Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.

  Journal of neurochemistry 20030301

• Anandamide-induced depressor effect in spontaneously hypertensive rats: role of the vanilloid receptor.

  Hypertension (Dallas, Tex. : 1979) 20030301

• Direct and indirect interactions between cannabinoid CB1 receptor and group II metabotropic glutamate receptor signalling in layer V pyramidal neurons from the rat prefrontal cortex.

  The European journal of neuroscience 20030301

• 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze.

  The European journal of neuroscience 20030301

• Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.

  Journal of medicinal chemistry 20030213

• Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study.

  Brain research 20030207

• Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a 'CB3' receptor.

  European journal of pharmacology 20030207

• Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.

  American journal of physiology. Regulatory, integrative and comparative physiology 20030201

• Cannabinoid influences on palatability: microstructural analysis of sucrose drinking after delta(9)-tetrahydrocannabinol, anandamide, 2-arachidonoyl glycerol and SR141716.

  Psychopharmacology 20030201

• Endogenous cannabinoids: a new target in the treatment of obesity.

  American journal of physiology. Regulatory, integrative and comparative physiology 20030201

• Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release.

  Journal of neurochemistry 20030201

• The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

  British journal of pharmacology 20030201

• Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors.

  Bioorganic & medicinal chemistry 20030117

• Concentration-dependent dual effect of anandamide on sensory neuropeptide release from isolated rat tracheae.

  Neuroscience letters 20030116

• R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsazepine-sensitive receptors.

  European journal of pharmacology 20030110

• Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.

  European journal of pharmacology 20030110

• Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract.

  European journal of pharmacology 20030110

• Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.

  Psychopharmacology 20030101

• Modulation of anxiety through blockade of anandamide hydrolysis.

  Nature medicine 20030101

• Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids.

  European journal of pharmacology 20030101

• A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.

  Neuroscience 20030101

• Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation.

  Neuroscience 20030101

• Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.

  Current pharmaceutical design 20030101

• Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex.

  Neuroscience 20030101

• Potential role of the cannabinoid receptor CB1 in rapid eye movement sleep rebound.

  Neuroscience 20030101

• Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons.

  Hippocampus 20030101

• Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats.

  Integrative physiological and behavioral science : the official journal of the Pavlovian Society 20030101

• In vivo imaging of the brain cannabinoid receptor.

  Chemistry and physics of lipids 20021231

• Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist.

  European journal of pharmacology 20021220

• Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes.

  Synapse (New York, N.Y.) 20021201

• SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study.

  Pharmacology, biochemistry, and behavior 20021201

• Tolerance to the disruptive effects of Delta(9)-THC on learning in rats.

  Pharmacology, biochemistry, and behavior 20021201

• The endocannabinoid system and the molecular basis of paralytic ileus in mice.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20021201

• N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor.

  Molecular pharmacology 20021201

• Design, expression, and characterization of a synthetic human cannabinoid receptor and cannabinoid receptor/ G-protein fusion protein.

  The journal of peptide research : official journal of the American Peptide Society 20021201

• Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia.

  European journal of pharmacology 20021115

• Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.

  Pharmacology, biochemistry, and behavior 20021101

• Anandamide induces cough in conscious guinea-pigs through VR1 receptors.

  British journal of pharmacology 20021101

• A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20021101

• Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity.

  European journal of pharmacology 20021011

• Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice.

  The Journal of pharmacology and experimental therapeutics 20021001

• Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.

  The Journal of pharmacology and experimental therapeutics 20021001

• Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs.

  Gastroenterology 20021001

• The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety.

  The European journal of neuroscience 20021001

• Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study.

  Brain research 20020906

• SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.

  Behavioural pharmacology 20020901

• Effects of anandamide on embryo implantation in the mouse.

  Life sciences 20020823

• Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.

  European journal of pharmacology 20020816

• Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts.

  Cardiovascular research 20020815

• Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020815

• Dose-dependent effects of Delta9-tetrahydrocannabinol on rates of local cerebral glucose utilization in rat.

  Synapse (New York, N.Y.) 20020801

• Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo.

  The Journal of pharmacology and experimental therapeutics 20020801

• The endogenous cannabinoid system controls extinction of aversive memories.

  Nature 20020801

• Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid.

  European journal of endocrinology 20020801

• The role of gap junctions in mediating endothelium-dependent responses to bradykinin in myometrial small arteries isolated from pregnant women.

  British journal of pharmacology 20020801

• Role of the endocannabinoid system in MDMA intracerebral self-administration in rats.

  British journal of pharmacology 20020801

• Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol.

  Psychopharmacology 20020801

• Blockade of cannabinoid CB(1) receptor function protects against in vivo disseminating brain damage following NMDA-induced excitotoxicity.

  Journal of neurochemistry 20020701

• Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats.

  Brain research. Developmental brain research 20020630

• Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).

  Journal of medicinal chemistry 20020620

• Boosting effect of morphine on alcohol drinking is suppressed not only by naloxone but also by the cannabinoid CB1 receptor antagonist, SR 141716.

  European journal of pharmacology 20020607

• Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent.

  American journal of physiology. Heart and circulatory physiology 20020601

• The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and non-diabetic rats.

  Neuropharmacology 20020601

• Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.

  The Journal of pharmacy and pharmacology 20020601

• Cannabinoids inhibit excitatory inputs to neurons in the shell of the nucleus accumbens: an in vivo electrophysiological study.

  The European journal of neuroscience 20020601

• Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids.

  The European journal of neuroscience 20020601

• The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells.

  Brain research. Molecular brain research 20020530

• Cannabinoid receptor antagonism and inverse agonism in response to SR141716A on cAMP production in human and rat brain.

  European journal of pharmacology 20020517

• Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats.

  European journal of pharmacology 20020517

• Delta(9)-tetrahydrocannabinol increases endogenous extracellular glutamate levels in primary cultures of rat cerebral cortex neurons: involvement of CB(1) receptors.

  Journal of neuroscience research 20020515

• Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020515

• Effect of opioid and cannabinoid receptor antagonism on orphanin FQ-induced hyperphagia in rats.

  European journal of pharmacology 20020510

• Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.

  Pain 20020501

• [Increase of the heart arrhythmogenic resistance and decrease of the myocardial necrosis zone during activation of cannabinoid receptors].

  Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova 20020501

• Cannabinoid CB(1) receptor blockade enhances the protective effect of melanocortins in hemorrhagic shock in the rat.

  European journal of pharmacology 20020419

• Interaction between vanilloid and glutamate receptors in the central modulation of nociception.

  European journal of pharmacology 20020329

• Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.

  European journal of pharmacology 20020329

• Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor.

  Journal of medicinal chemistry 20020328

• Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.

  Journal of neuroscience research 20020315

• The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020301

• Effect of the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNF-alpha production by human mononuclear cells.

  International immunopharmacology 20020301

• SR 141716A prevents delta 9-tetrahydrocannabinol-induced spatial learning deficit in a Morris-type water maze in mice.

  Progress in neuro-psychopharmacology & biological psychiatry 20020201

• Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides.

  Investigative ophthalmology & visual science 20020201

• Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20020201

• CB(1) receptor antagonist SR141716A inhibits Ca(2+)-induced relaxation in CB(1) receptor-deficient mice.

  Hypertension (Dallas, Tex. : 1979) 20020201

• Evaluation of the reinforcing effects of the cannabinoid CB1 receptor antagonist, SR141716, in rhesus monkeys.

  European journal of pharmacology 20020125

• The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.

  The Journal of pharmacology and experimental therapeutics 20020101

• Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat.

  Gastroenterology 20020101

• CB(1) receptor antagonist SR141716A increases capsaicin-evoked release of Substance P from the adult mouse spinal cord.

  British journal of pharmacology 20020101

• Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.

  Pharmacology, biochemistry, and behavior 20020101

• Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine.

  Pharmacology, biochemistry, and behavior 20020101

• Rimonabant. SR 141716, SR 141716a.

  Drugs in R&D 20020101

• Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20011201

• Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors.

  The Journal of pharmacology and experimental therapeutics 20011201

• Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo.

  Journal of neurophysiology 20011201

• Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats.

  Psychopharmacology 20011201

• Characteristics of learning and memory impairment induced by delta9-tetrahydrocannabinol in rats.

  Japanese journal of pharmacology 20011201

• Activity of SR141716 on post-reinforcement pauses in operant responding for sucrose reward in rats.

  Behavioural pharmacology 20011201

• Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues.

  European journal of pharmacology 20011123

• Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats.

  Life sciences 20011121

• Rapid tolerance to Delta(9)-tetrahydrocannabinol and cross-tolerance between ethanol and Delta(9)-tetrahydrocannabinol in mice.

  European journal of pharmacology 20011116

• Exogenous anandamide protects rat brain against acute neuronal injury in vivo.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20011115

• The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats.

  European journal of pharmacology 20011102

• Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice.

  British journal of pharmacology 20011101

• Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels.

  British journal of pharmacology 20011101

• Anandamide administration into the ventromedial hypothalamus stimulates appetite in rats.

  British journal of pharmacology 20011101

• Effects of cannabinoids on adrenaline release from adrenal medullary cells.

  British journal of pharmacology 20011101

• The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2.

  European journal of pharmacology 20011026

• Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels.

  Journal of neuroscience research 20011015

• Interaction of anandamide with the M(1) and M(4) muscarinic acetylcholine receptors.

  Brain research 20011005

• Cannabinoids inhibit nitric oxide production in bone marrow derived feline macrophages.

  Veterinary immunology and immunopathology 20011001

• Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation.

  British journal of pharmacology 20011001

• Cannabinoid activity curtails cocaine craving.

  Nature medicine 20011001

• A cannabinoid mechanism in relapse to cocaine seeking.

  Nature medicine 20011001

• Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries.

  British journal of pharmacology 20011001

• Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects.

  European journal of pharmacology 20010928

• Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.

  The Journal of pharmacology and experimental therapeutics 20010901

• Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms.

  Pain 20010901

• Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze.

  Neuropharmacology 20010901

• A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus.

  British journal of pharmacology 20010901

• Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors.

  British journal of pharmacology 20010901

• Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters.

  Pharmacology, biochemistry, and behavior 20010901

• Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration.

  Alcoholism, clinical and experimental research 20010901

• SR141716, a CB1 receptor antagonist, decreases the sensitivity to the reinforcing effects of electrical brain stimulation in rats.

  Psychopharmacology 20010901

• Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity.

  Neuroscience letters 20010831

• The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus.

  European journal of pharmacology 20010831

• Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands.

  European journal of pharmacology 20010803

• The cannabinoid receptor agonist WIN 55,212-2 regulates glutamate transmission in rat cerebral cortex: an in vivo and in vitro study.

  Cerebral cortex (New York, N.Y. : 1991) 20010801

• Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor.

  Cancer research 20010801

• (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide.

  Psychopharmacology 20010801

• Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats.

  Psychopharmacology 20010801

• Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor.

  Neuroreport 20010720

• CB1 receptor mediated analgesia from the Nucleus Reticularis Gigantocellularis pars alpha is activated in an animal model of neuropathic pain.

  Brain research 20010720

• Functional interaction between opioid and cannabinoid receptors in drug self-administration.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010715

• Endogenously produced cannabinoids and liver cirrhosis.

  Lancet (London, England) 20010707

• Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors.

  European journal of pharmacology 20010706

• Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.

  The Journal of pharmacology and experimental therapeutics 20010701

• Identification of two distinct vasodilator pathways activated by ATP in the mesenteric bed of the rat.

  British journal of pharmacology 20010701

• Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation.

  The European journal of neuroscience 20010701

• The central cannabinoid receptor inactivation suppresses endocrine reproductive functions.

  Biochemical and biophysical research communications 20010608

• The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain.

  British journal of pharmacology 20010601

• Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates.

  Psychopharmacology 20010601

• Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse.

  Life sciences 20010525

• Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20010515

• Cannabinoid receptor agonist-stimulated [35S]guanosine triphosphate gammaS binding in the brain of C57BL/6 and DBA/2 mice.

  Journal of neuroscience research 20010515

• Delta9-tetrahydrocannabinol enhances cortical and hippocampal acetylcholine release in vivo: a microdialysis study.

  European journal of pharmacology 20010511

• Critical role of the endogenous cannabinoid system in mouse pup suckling and growth.

  European journal of pharmacology 20010511

• Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice.

  The Journal of pharmacology and experimental therapeutics 20010501

• Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons.

  The Journal of physiology 20010501

• The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.

  Pain 20010501

• Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed.

  European journal of pharmacology 20010420

• Leptin-regulated endocannabinoids are involved in maintaining food intake.

  Nature 20010412

• Effect of vanilloid drugs on gastrointestinal transit in mice.

  British journal of pharmacology 20010401

• Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.

  Archives of general psychiatry 20010401

• Cannabinoid antagonists: a treatment in search of an illness.

  Archives of general psychiatry 20010401

• Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: evaluation of the interest in pharmacotherapy of opioid addiction.

  British journal of pharmacology 20010401

• Pharmacological properties of cannabinoid receptors in the avian brain: similarity of rat and chicken cannabinoid1 receptor recognition sites and expression of cannabinoid2 receptor-like immunoreactivity in the embryonic chick brain.

  Pharmacology & toxicology 20010401

• Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses.

  Nature 20010329

• Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2.

  European journal of pharmacology 20010323

• Inhibitory effects of SR141716A on G-protein activation in rat brain.

  European journal of pharmacology 20010302

• Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception.

  Neuropharmacology 20010301

• Novel pyrazole cannabinoids: insights into CB(1) receptor recognition and activation.

  The Journal of pharmacology and experimental therapeutics 20010301

• Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones.

  British journal of pharmacology 20010301

• Cannabinoidergic and opioidergic inhibition of spinal reflexes in the decerebrated, spinalized rabbit.

  Neuropharmacology 20010301

• Enhanced acetylcholine release in the hippocampus of cannabinoid CB(1) receptor-deficient mice.

  British journal of pharmacology 20010301

• Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens.

  British journal of pharmacology 20010301

• 2-Arachidonoylglycerol, a candidate of endothelium-derived hyperpolarizing factor.

  European journal of pharmacology 20010301

• Endogenous cannabinoid anandamide increases heart resistance to arrhythmogenic effects of epinephrine: role of CB(1) and CB(2) receptors.

  Bulletin of experimental biology and medicine 20010301

• Cannabinoids and pain.

  Current opinion in investigational drugs (London, England : 2000) 20010301

• Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system.

  European journal of pharmacology 20010216

• Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20010201

• Endocannabinoids control spasticity in a multiple sclerosis model.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010201

• Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.

  British journal of pharmacology 20010201

• Regional differences in anandamide- and methanandamide-induced membrane potential changes in rat mesenteric arteries.

  The Journal of pharmacology and experimental therapeutics 20010201

• delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1.

  European journal of biochemistry 20010201

• Human platelets bind and degrade 2-arachidonoylglycerol, which activates these cells through a cannabinoid receptor.

  European journal of biochemistry 20010201

• Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide.

  British journal of pharmacology 20010201

• Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats.

  Naunyn-Schmiedeberg's archives of pharmacology 20010201

• Effects of SR141716A on ethanol and sucrose self-administration.

  Alcoholism, clinical and experimental research 20010201

• The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1.

  The EMBO journal 20010115

• Systemic and portal hemodynamic effects of anandamide.

  American journal of physiology. Gastrointestinal and liver physiology 20010101

• CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum.

  Journal of neurophysiology 20010101

• Cannabinoid CB1 receptor-mediated inhibition of acetylcholine release in the brain of NMRI, CD-1 and C57BL/6J mice.

  Naunyn-Schmiedeberg's archives of pharmacology 20010101

• Synergistic efects of opioid and cannabinoid antagonists on food intake.

  Psychopharmacology 20010101

• Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.

  Pharmacology, biochemistry, and behavior 20010101

• Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew.

  Pharmacology, biochemistry, and behavior 20010101

• Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice.

  Pharmacology, biochemistry, and behavior 20010101

• Conditioned place preference induced by the cannabinoid agonist CP 55,940: interaction with the opioid system.

  Neuroscience 20010101

• Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus.

  Neuroscience 20010101

• Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation.

  Advances in experimental medicine and biology 20010101

• Involvement of central and peripheral cannabinoid receptors in the regulation of heart resistance to arrhythmogenic effects of epinephrine.

  Bulletin of experimental biology and medicine 20001101

• The anandamide transport inhibitor AM404 activates vanilloid receptors.

  European journal of pharmacology 20000512

• Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.

  The Journal of biological chemistry 20000107

• HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.

  Proceedings of the National Academy of Sciences of the United States of America 19991207

• Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.

  Proceedings of the National Academy of Sciences of the United States of America 19991123

• The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats.

  European journal of pharmacology 19991112

• CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats.

  Behavioural brain research 19991001

• Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.

  European journal of pharmacology 19990625

• The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells.

  The Journal of pharmacology and experimental therapeutics 19990301

• Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain.

  The European journal of neuroscience 19980501

• Comparative receptor binding analyses of cannabinoid agonists and antagonists.

  The Journal of pharmacology and experimental therapeutics 19980401

• Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells.

  Life sciences 19980101

• The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease.

  Experimental neurology 19971101

• Regional differences in cannabinoid receptor/G-protein coupling in rat brain.

  The Journal of pharmacology and experimental therapeutics 19970901

• delta 9-Tetrahydrocannabinol increases activity of tyrosine hydroxylase in cultured fetal mesencephalic neurons.

  Journal of molecular neuroscience : MN 19970401

• Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A.

  Journal of neurochemistry 19970101

• Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist.

  Neuroscience letters 19961213

• Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.

  The Journal of biological chemistry 19960322

• Biochemical and pharmacological characterization of cannabinoid binding sites using [3H]SR141716A.

  Neuroreport 19960227

• Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain.

  Life sciences 19960101

• Anandamide, an endogenous cannabinoid, inhibits Shaker-related voltage-gated K+ channels.

  Neuropharmacology 19960101

• Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.

  The Biochemical journal 19951201

• SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

  FEBS letters 19940822

• Government freezes administrators' salaries.

  Dimensions in health service 19760101

• Fasting induces CART down-regulation in the zebrafish nervous system in a cannabinoid receptor 1-dependent manner.

  Molecular endocrinology (Baltimore, Md.)